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SUMMARY 
Incidence: 
 An average of 18,500 invasive (excluding non-melanoma skin) cancers was diagnosed per year between 2008 
and 2010, equivalent to an incidence rate of 423 cases per 100,000 per year.   
 Incidence rate was 26% higher in men than in women and cumulative lifetime risk of diagnosis was 1 in 3 for 
males and 1 in 4 for females. 
 Excluding non-melanoma skin cancers, prostate (3014 cases per year) and female breast cancer (2767 cases per 
year) were the most frequently diagnosed cancers in men and women respectively.  Colorectal (2387 cases per 
year) and lung (2110 cases per year) cancers were the 2nd and 3rd most commonly diagnosed cancers in both 
sexes. 
Mortality: 
 A total of 8,316 deaths from cancer were recorded in 2010, equivalent to a mortality rate of 175 deaths per 
100,000 per year.  Cancer was the second leading cause of death in Ireland after diseases of the circulatory 
system. 
 Cancer mortality rate was 35% higher in men than in women and cumulative lifetime risk of death from cancer 
was 1 in 8 for males and 1 in 10 for females. 
 Lung cancer (1693 total deaths in 2010) was the leading cause of cancer death in both sexes representing 18% 
of female and 22% of male cancer deaths. Female breast, colorectal and prostate cancers represented the next 
most common cancer deaths and together with lung cancer made up almost half (46%) of all cancer deaths in 
2010. 
International comparisons in incidence and mortality: 
 For all invasive cancers combined and the 4 most common cancers, incidence rates in Ireland ranked amongst 
the top 10 highest in Europe. 
 Mortality rates in Ireland ranked lower generally and were close to values recorded in the UK for all cancers 
combined and similar to the EU average for colorectal cancers. 
 Lung cancer incidence and mortality in Irish females was substantially higher than the EU average but rates in 
Irish males were lower than average. 
Prevalence: 
 A total of 104,300 cancer patients diagnosed since January 1994 were still alive at the end of 2010, representing 
47% of all females and 40% of all males diagnosed. 
 38,000 of these patients had been diagnosed within the previous 3 years which provides an estimate of the 
number of patients likely to be either still undergoing active therapy or clinical follow-up. 
Trends in incidence and mortality: 
 Total cancer case numbers in 2010 were 56% higher than in 1994, equivalent to an annual percentage change in 
incidence rate of 1.1% in females and 1.2% in males.  Since 1994, cancer mortality has declined by 1% in males 
and 1.4% in females annually resulting in a reduction in all cancer mortality/incidence ratios from 6 to 4 deaths 
for every 10 cases diagnosed. 
 All-cancer mortality rates increased from the early 1950’s to maximum levels during late 1980’s-mid 1990’s and 
subsequently declined in recent years; a pattern observed for most individual cancer types and in both sexes.  
Lung cancer mortality rates in females however have continued to increase. 
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Treatment: 
 Little difference was observed in treatment between males and females, but patients aged less than 65 were 
more likely to have surgery, chemotherapy and radiotherapy.  Older patients aged 75 years and over were less 
likely to have tumour-directed treatment. 
 The proportion of patients having chemotherapy increased for a wide range of cancers from 2000-2004 to 
2005-2009 while percentages of patients undergoing radiotherapy fell for testicular cancer and Hodgkin’s 
lymphoma. 
Survival: 
 Significant improvements in survival have been observed over time in both sexes, particularly in males.  This has 
resulted in an almost equalisation of overall 5 year relative survival rates between males and females in recent 
years. 
 Cancer of the testis, prostate, female thyroid and female melanoma had the best survival, all with 5 year 
relative survival rates of over 90%.  In contrast patients with pancreatic cancer had the poorest survival overall, 
with 5 year survival rates of less than 10%.  Cancers of the liver, lung, oesophagus, brain and stomach also had 
poor survival rates, all less than 20%. 
Person Years of Life Lost (YLL): 
 It is estimated that an average of 16 years of life were lost for females and 13 for males dying from cancer in 
2010. 
 Although average age at death increased for most cancers from 1995 to 2010, the average person years of life 
lost increased, reflecting increased life expectancy of the population generally. 
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1.  INCIDENCE   
An annual average of approximately 32,500 cancers was registered between 2008 and 2010 inclusive, representing an overall 
incidence rate of 727 cases per 100,000 per year (Table 1).  Over 18% of these were non-invasive cancers (in-situ tumours, 
cancers of uncertain behaviour and benign brain and CNS tumours) and almost 25% were non-melanoma skin cancers (NMSC, 
7,986 cases per year).   Figures for all invasive cancers, excluding NMSC, represented 57% of all registered cases and over 18,500 
were registered annually; equivalent to an incidence rate of 423 cases per 100,000 per year.  Incidence rate for all invasive 
cancers excluding NMSC was 26% higher for men than for women (as was previously observed in 2007-2009 figures), and 
cumulative lifetime risk, although slightly increased compared to previously published data, remains approximately 1 in 3 for 
men and 1 in 4 for women.  Summary incidence data for 2008-2010 for individual cancers by ICD10 code is listed in Appendix I. 
 
Table 1: Annual average incidence for the main cancers, 2008-2010 
 cases rate/100,000 risk (%) to age 75 years % all invasive‡ 
 females males total females males total females males total females males total 
mouth & pharynx 119 227 346 5.2 11.3 8.1 0.4 1.0 0.7 1.4 2.3 1.9 
oesophagus 130 242 372 5.1 11.9 8.4 0.4 1.0 0.7 1.5 2.5 2.0 
stomach 191 332 523 7.6 16.1 11.5 0.5 1.2 0.9 2.2 3.4 2.8 
colorectal 998 1,389 2,387 41.1 67.8 53.4 3.1 5.2 4.1 11.4 14.2 12.9 
pancreas 227 248 475 9.0 12.3 10.5 0.6 1.0 0.8 2.6 2.5 2.6 
lung 879 1,231 2,110 36.9 60.0 47.3 2.9 4.6 3.7 10.0 12.5 11.4 
melanoma 463 349 812 19.8 16.7 18.2 1.6 1.3 1.4 5.3 3.6 4.4 
breast 2,767 22 2,789 127.0 1.1 65.5 10.0 0.1 5.2 31.6 0.2 15.0 
cervix 308 - 308 13.5 - - 1.0 - - 3.5 - - 
corpus uteri 389 - 389 18.0 - - 1.6 - - 4.4 - - 
ovary 345 - 345 15.2 - - 1.2 - - 3.9 - - 
other gynaecological cancers* 99 - 99 4.2 - - 0.3 - - 1.1 - - 
prostate - 3,014 3,014 - 149.4 - - 12.7 - - 30.7 - 
testis - 175 175 - 7.2 - - 0.5 - - 1.8 - 
kidney 174 312 486 7.5 15.2 11.2 0.6 1.2 0.9 2.0 3.2 2.6 
bladder 124 310 434 4.8 15.2 9.4 0.3 1.0 0.7 1.4 3.2 2.3 
brain & CNS 151 193 344 6.7 9.2 7.9 0.5 0.8 0.7 1.7 2.0 1.9 
all lymphomas 363 420 782 15.7 20.0 17.7 1.3 1.6 1.4 4.1 4.3 4.2 
    Hodgkin's lymphoma 57 71 128 2.5 3.2 2.9 0.2 0.3 0.2 0.7 0.7 0.7 
    non-Hodgkin’s lymphoma 306 349 654 13.2 16.8 14.9 1.1 1.3 1.2 3.5 3.6 3.5 
multiple myeloma 101 137 238 4.1 6.7 5.3 0.3 0.5 0.4 1.2 1.4 1.3 
leukaemia 191 279 470 8.1 13.4 10.5 0.6 1.0 0.8 2.2 2.8 2.5 
non-melanoma skin (NMSC) 3,575 4,410 7,986 147.4 214.7 177.6 10.7 15.1 12.9 - - - 
other invasive cancers, not listed 742 930 1,672 29.9 45.0 37.0 2.1 3.4 2.7 8.5 9.5 9.0 
all invasive cancers  (excluding NMSC) 8,761 9,809 18,570 379.6 478.2 422.8 26.2 32.5 29.3 100 100 100 
             
non-invasive cancers 4,563 1,381 5,944 186.3 67.0 126.6 13.3 5.1 9.3 - - - 
             
all registered cancers 16,899 15,600 32,499 713.3 759.9 727.0 42.9 45.6 44.2 - - - 
rate: number of cases per 100,000 population per year (European standard population) 
risk: cumulative lifetime risk of cancer diagnosis to age 75 years, expressed as a percentage 
‡ all invasive cancers excluding non melanoma skin cancers (NMSC) 
*cancers of the vulva, vagina, uterus (NOS), other female genital and placenta 
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Figure 1: Relative frequency of the main invasive cancers diagnosed, 2008-2010 
  
 
 
Of all invasive cancers registered, non-melanoma skin 
cancer (NMSC) represented by far the most common 
cancer, representing 29% and 31% of all cases in women 
and men respectively (Figure 1).   
 
If figures are examined where NMSC are excluded, 
female breast and prostate cancer were the most 
commonly diagnosed cancers overall and comprised 
almost one-third of all cancers in women and men 
respectively (Table 2).  Between 2008 and 2010, 
colorectal and lung cancer were ranked as the 2nd and 3rd 
most common cancers in both sexes respectively – as 
previously reported. However it is worth noting that 
their combined relative proportion of all invasive 
cancers is still less than that for breast and prostate 
alone.  The remaining cancers in both sexes formed a 
much smaller proportion of the total, with melanoma 
and corpus uteri representing the next most common 
cancers in women and melanoma and lymphoma (all 
subtypes combined) in men. 
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Table 2: Ranking of the most commonly diagnosed invasive cancers  
(excluding NMSC), 2008-2010 
 females males 
 % rank % rank 
breast 31.6 1 0.2 16 
prostate - - 30.7 1 
colorectal 11.4 2 14.2 2 
lung 10.0 3 12.5 3 
melanoma 5.3 4 3.6 5 
corpus uteri 4.4 5 - - 
all lymphomas 4.1 6 4.3 4 
stomach 2.2 10 3.4 6 
pancreas 2.6 9 2.5 10 
bladder 1.4 15 3.2 8 
kidney 2.0 12 3.2 7 
leukaemia 2.2 11 2.8 9 
oesophagus 1.5 14 2.5 11 
ovary 3.9 7 - - 
brain & CNS 1.7 13 2.0 13 
cervix 3.5 8 - - 
mouth & pharynx 1.4 16 2.3 12 
multiple myeloma 1.2 17 1.4 15 
testis - - 1.8 14 
other invasive cancers, not listed 9.6  9.5  
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2.  MORTALITY  
In 2010, cancer was the second most common cause of death, after diseases of the circulatory system, and a total of 8,316 
deaths from cancer were reported.  This represented approximately 30% of all deaths in 2010 and a mortality rate of 175 deaths 
per 100,000 per year (Table 3).  Almost all cancer deaths were from invasive cancers (98%).  All-cancer mortality rates were 
approximately 35% higher in men than in women and the lifetime risk of dying from cancer was 1 in 8 for men and slightly over 1 
in 10 for women.  Lung cancer was the single most common cause of cancer death overall with a mortality rate of 36.5 deaths 
per 100,000 per year, representing 20% of all cancer deaths overall, 18.1% in females and 22.4% in males.  Summary mortality 
data for cancer deaths by ICD10 code is listed in Appendix II. 
Table 3: Number of deaths and mortality from the main cancers, 2010        
 deaths rate/100,000 risk (%) to age 75 years % all cancer deaths 
 females males total females males total females males total females males total 
             
mouth & pharynx 45 79 124 1.7 3.8 2.7 0.1 0.3 0.2 1.1 1.8 1.5 
oesophagus 113 220 333 4.1 10.4 7.1 0.2 0.8 0.5 2.9 5.0 4.0 
stomach 136 180 316 5.1 8.4 6.7 0.3 0.6 0.5 3.4 4.1 3.8 
colorectal 407 535 942 15.2 25.3 19.7 0.9 1.7 1.3 10.3 12.2 11.3 
pancreas 228 244 472 8.6 11.6 10.0 0.6 0.9 0.8 5.8 5.6 5.7 
lung 716 977 1693 28.6 46.4 36.5 2.2 3.4 2.8 18.1 22.4 20.4 
melanoma 60 85 145 2.3 4.0 3.1 0.2 0.3 0.2 1.5 1.9 1.7 
breast 649 10 659 26.5 0.5 14.3 2.1 0.0 1.1 16.4 0.2 7.9 
cervix 88 - 88 3.8 - - 0.3 - - 2.2 - - 
corpus uteri 73 - 73 2.9 - - 0.3 - - 1.8 - - 
ovary 286 - 286 11.8 - - 1.0 - - 7.2 - - 
other gynaecological cancers* 55 - 55 2.1 - - 0.1 - - 1.4 - - 
prostate - 533 533 - 25.3 - - 1.0 - - 12.2 - 
testis - 5 5 - 0.2 - - 0.0 - - 0.1 - 
kidney 57 127 184 2.1 6.1 3.9 0.1 0.4 0.3 1.4 2.9 2.2 
bladder 65 120 185 2.3 5.6 3.7 0.2 0.2 0.2 1.6 2.7 2.2 
brain & CNS 96 139 235 4.2 6.5 5.3 0.3 0.5 0.4 2.4 3.2 2.8 
all lymphomas 106 144 250 4.0 6.7 5.3 0.3 0.4 0.4 2.7 3.3 3.0 
    Hodgkin's lymphoma 8 10 18 0.3 0.5 0.4 0.0 0.0 0.0 0.2 0.2 0.2 
    non-Hodgkin’s lymphoma 98 134 232 3.8 6.3 4.9 0.3 0.4 0.3 2.5 3.1 2.8 
multiple myeloma 85 67 152 3.0 3.2 3.1 0.2 0.2 0.2 2.2 1.5 1.8 
leukaemia 87 128 215 3.2 6.1 4.5 0.2 0.4 0.3 2.2 2.9 2.6 
non-melanoma skin (NMSC) 26 57 83 0.8 2.7 1.6 0.0 0.1 0.1 0.7 1.3 1.0 
other invasive cancers, not listed 487 620 1,107 17.8 29.3 23.2 1.2 2.0 1.6 12.3 14.2 13.3 
all invasive cancers 3,865 4,270 8,135 150.2 202.2 171.7 10.4 12.6 11.5 97.9 97.7 97.8 
             
non-invasive cancers 82 99 181 2.7 4.5 3.4 0.1 0.2 0.1 2.1 2.3 2.2 
             
all cancer deaths 3,947 4,369 8,316 152.9 206.7 175.2 10.5 12.7 11.6 100 100 100 
rate: number of deaths per 100,000 population per year (European standard population) 
risk: cumulative lifetime risk of cancer death to age 75 years, expressed as a percentage 
*Cancers of the vulva, vagina, uterus (NOS), other female genital and placenta 
Mortality data provided by the Central Statistics Office (www.cso.ie) 
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Figure 2: Relative frequency of the main cancer deaths, 2010 
  
 
 
As previously reported, lung cancer is now the leading cause of 
cancer death in women as well as in men, and together with 
breast and colorectal cancer, made up 44% of all female cancer 
deaths in 2010 (Figure 2).  In men, prostate and colorectal cancer 
both comprised approximately 12% of all cancer deaths and 
together with lung cancer represented nearly half of all deaths 
from cancer in 2010.  Deaths from cancers of the ovary, 
pancreas, stomach and oesophagus were ranked between the 4th 
and 7th most common cancer deaths in women and men (Table 
4) – their comparatively greater proportion of cancer deaths 
compared to cancer incidence (Table 3) indicating their relatively 
high mortality rates compared to other cancer types. 
 
 
 
Mortality data provided by the Central Statistics Office  
(www.cso.ie) 
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Table 4: Ranking of the most common cancer deaths, 2010 
 females males 
 % rank % rank 
lung 18.1% 1 22.4% 1 
breast 16.4% 2 - - 
colorectal 10.3% 3 12.2% 2 
prostate - - 12.2% 3 
ovary 7.2% 4 - - 
pancreas 5.8% 5 5.6% 4 
stomach 3.4% 6 4.1% 6 
oesophagus 2.9% 7 5.0% 5 
lymphoma 2.7% 8 3.3% 7 
brain & CNS 2.4% 9 3.2% 8 
cervix 2.2% 10 - - 
leukaemia 2.2% 11 2.9% 9 
multiple myeloma 2.2% 12 1.5% 14 
kidney 1.4% 16 2.9% 10 
bladder 1.6% 14 2.7% 11 
corpus uteri 1.8% 13 - - 
melanoma 1.5% 15 1.9% 12 
mouth & pharynx 1.1% 18 1.8% 13 
other cancer deaths 16.5%  18.1%  
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3.  PERSON YEARS OF LIFE LOST (YLL) DUE TO CANCER   
Estimates of the years of life lost due to cancer (YLL) are generated by comparing the life expectancy at each single year of age 
with the number of deaths from cancer that occurred at that age.  Results for deaths in 1995 and in 2010 are shown, separately 
for females and males, in Table 5.  
 
A total of 51,693 YLL was estimated for women who died from cancer in 1995, an average of 15 years per person (Table 5a).  
This increased to 62,371 YLL in 2010, although the average per person changed little (15.8 years). The greatest percentage of YLL 
in women was from breast cancer, making up almost 23% of all YLL in 1994 and 19% in 2010.  Lung and colorectal cancers, the 
Table 5: Comparison of the years of life lost (YLL) due to cancer, 1995 and 2010 
(a) Females  1995   2010 
 Average 
age at 
death 
Total 
YLL 
average 
YLL 
% of all 
years 
lost 
 Average 
age at 
death 
Total 
YLL 
average 
YLL 
% of all 
years 
lost 
breast 65.9 11,798 18.0 22.8%  68.5 11,864 18.3 19.0% 
lung 71.0 7,438 13.9 14.4%  71.5 11,117 15.5 17.8% 
colorectal 73.0 5,450 12.9 10.5%  73.8 5,803 14.3 9.3% 
ovary 67.4 3,320 16.7 6.4%  69.8 4,853 17.0 7.8% 
pancreas 74.1 2,079 12.0 4.0%  74.8 3,018 13.2 4.8% 
brain & CNS 62.9 1,882 20.5 3.6%  62.8 2,175 22.7 3.5% 
stomach 73.7 1,881 12.5 3.6%  72.3 2,121 15.6 3.4% 
leukaemia 65.4 1,542 19.3 3.0%  71.6 1,448 16.6 2.3% 
oesophagus 74.0 1,496 11.9 2.9%  75.2 1,479 13.1 2.4% 
lymphoma 70.2 1,394 14.8 2.7%  73.0 1,558 14.7 2.5% 
kidney 68.4 735 16.7 1.4%  73.1 840 14.7 1.3% 
bladder 76.5 487 10.6 0.9%  75.2 890 13.7 1.4% 
all cancer deaths 70.0 51,693 15.0 100%  71.7 62,471 15.8 100% 
          
diseases of the circulatory system       40,315 8.5  
diseases of the respiratory system       13,945 8.0  
          
(b) Males  1995   2010 
 Average 
age at 
death 
Total 
YLL 
average 
YLL 
% of all 
years 
lost 
 Average 
age at 
death 
Total 
YLL 
average 
YLL 
% of all 
years 
lost 
lung 70.0 11,943 11.6 24.6%  71.0 12,995 13.3 22.4% 
colorectal 70.3 6,363 11.6 13.1%  72.0 6,844 12.8 11.8% 
prostate 76.9 4,031 7.8 8.3%  79.3 4,473 8.4 7.7% 
brain & CNS 56.7 3,022 21.7 6.2%  59.7 3,092 22.2 5.3% 
stomach 70.7 2,949 11.4 6.1%  68.9 2,693 15.0 4.6% 
pancreas 69.2 2,180 12.5 4.5%  70.9 3,268 13.4 5.6% 
lymphoma 62.6 2,177 17.3 4.5%  70.9 1,970 13.7 3.4% 
oesophagus 69.5 1,970 12.1 4.1%  68.9 3,267 14.9 5.6% 
leukaemia 66.2 1,532 15.3 3.2%  68.3 2,053 16.0 3.5% 
bladder 76.6 937 8.1 1.9%  77.0 1,168 9.7 2.0% 
kidney 69.6 777 12.1 1.6%  70.1 1,818 14.3 3.1% 
all cancer deaths 70.2 48,568 11.8 100%  71.5 57,996 13.3 100% 
          
diseases of the circulatory system       53,579 11.0  
diseases of the respiratory system       13,758 9.0  
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other most common causes of cancer death, together represented over 25% of all YLL in women in 1995 and 27% in 2010, with 
the proportion of years lost due to lung cancer in particular increasing substantially.  For most cancers, the average YLL 
increased between 1995 and 2010, probably a reflection of the generally greater life expectancy for women in 2010 compared 
to 1995 as the average age at death from cancer increased during this time (with the exception of stomach, bladder and brain & 
CNS cancers).  A decline in the YLL for leukaemia and kidney cancers in females between 1995 and 2010 is a likely indicator of 
improved survival rates for these cancers. It is worth noting that deaths from brain and CNS cancers represented the single 
greatest average YLL in women in 1995 and again in 2010.  Although contributing less than 4% of YLL from all cancers, their 
comparatively young age at incidence (compared to some other more common cancers) and poor prognosis resulted in an 
average of over 20 years of life lost for these patients.  Finally, in 2010, although the total number of female deaths from cancer 
ranked second, after diseases of the circulatory system, it is interesting to note that the total YLL for the latter in 2010 was 
40,315 (35% less than that for all cancer deaths).    
 
An overall average of 11.8 YLL was estimated for men who died from cancer in 1995 and this increased to 13.3 years per person 
or almost 58,000 total YLL in 2010 (Table 5b).  As for females, the most commonly diagnosed cancers comprised the bulk of all 
years of life lost; with prostate, lung and colorectal cancers together representing 46% of all YLL in 1995 and 42% in 2010.  It is 
notable that, contrary to observations in females, the percentage YLL from lung cancer in males decreased between 1995 and 
2010 (from 24.6% to 22.4%). As observed for females, the average YLL for most individual cancers increased in 2010 despite 
increases in the average age at death from most cancers (except for oesophagus and stomach), reflecting the greater life 
expectancy for males in 2010 compared to 1995.  A fall in average YLL was observed for male lymphoma - from 17.3 to 13.7, a 
result of increased average age at death in 2010 (70.9) compared to 1995 (62.6) and significant improvements in survival.   As 
with females, brain and CNS represented the single greatest average YLL of 22 years approximately, considerably higher than 
that for the 3 most common cancers.  Although total YLL for all cancer deaths in men in 2010 (57,996) was also higher than that 
estimated for deaths from circulatory disease (53,579), this was to a much lesser extent than that observed for females. 
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In the 15 year period from 1995 to 2010, total YLL increased from 100,261 to 120,467 (an increase of 20% approximately).  
Greatest relative increases in total YLL were observed for deaths from cancers of the pancreas, lung, ovary and bladder in 
women and for deaths from cancers of the oesophagus, pancreas and kidney in men (Figure 3).  The large increase in YLL for 
female lung cancer between 1995 and 2010 is notable – although total YLL for lung cancer in men increased by less than 10%, 
female total YLL from lung cancer increased by 49%, an indicator of the increasing importance of lung cancer mortality in 
women. 
 
Figure 3: Years of life lost (YLL) due to common cancers, 1995 and 2010 
Females Males 
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4.  INCIDENCE AND MORTALITY: IRELAND AND OTHER EUROPEAN COUNTRIES, 2012 
The European Cancer Observatory (http://eco.iarc.fr/Default.aspx) has recently produced estimates of national cancer incidence 
and mortality for all European countries for 2012. (1)  A standard methodology was used so that all countries could be included in 
the estimates.  Although rates generated may differ to those produced by individual countries, it is the only standard by which 
cancer incidence and mortality can be compared directly between countries.  A series of bar-charts showing the incidence and 
mortality for some of the main cancers are shown in Figure 4.  Data is shown for 25 of the current EU-27 countries with Norway 
and Switzerland (both outside EU) also included.  The ‘EU overall’ figure shown in the graphs refers to the average for the 27 EU 
countries (i.e. the 25 EU countries listed plus Cyprus and Malta).  Additional graphs for other common cancers are shown in 
Appendix III. 
All invasive cancers 
Estimates for Ireland indicate that cancer incidence here was amongst the highest in Europe, with females ranked 5th and males 
8th of 27 countries (Figure 4a).  Incidence rates were 15% and 10% higher than the overall EU average respectively.  However 
variability between countries was low and Irish incidence rates were generally close to those found in several other north 
western European countries.  Mortality rates tended to vary to a greater degree than incidence with Irish females ranked 6th and 
males 21st highest overall.  Both female and male mortality rates in Ireland were close to those found for the UK - female rates in 
Ireland were 13% higher and male rates 9% lower than the EU average.  The Irish mortality/incidence ratio was similar to that 
for the EU overall with approximately 4 deaths for every 10 incident cases. 
Figure 4a: Estimated cancer incidence and mortality in Europe 2012, all invasive cancers (excluding non-melanoma skin) 
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Colorectal cancer 
Colorectal cancer incidence rates for females and males in Ireland ranked 7th and 9th highest respectively of 27 European 
countries (Figure 4b).  Female rates were 14% higher than the EU average and male rates were 10% higher.  However Irish 
mortality rates were comparatively lower; female rates were the same as those calculated for the EU overall and ranked 17th out 
of 27, while male rates ranked 15th.  Mortality/incidence ratios for Irish males were the same as that calculated for the EU 
overall; 4 deaths for every 10 incident cases, but Irish female ratios were lower than the EU average; 3 deaths (compared to 4) 
for every 10 diagnosed cases. 
 
Figure 4b: Estimated cancer incidence and mortality in Europe 2012, colorectal cancer 
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in a number of other north European countries, particularly Sweden, Norway, Denmark, Netherlands and UK, the ratio between 
males and females was much lower – which may be an indicator of different smoking prevalence patterns in males and females.  
Mortality/incidence ratios for both sexes in Ireland were lower than the EU average however with 7 female deaths in Ireland for 
every 10 cases (compared to 8 deaths in the EU) and 8 male deaths in Ireland for every 10 cases diagnosed (9 deaths in the EU). 
 
Figure 4c: Estimated cancer incidence and mortality in Europe 2012, lung cancer 
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Female breast cancer 
Female breast cancer incidence in Ireland was 12.5% higher than the EU average and ranked 6th highest of 27 countries overall 
(Figure 4d).  In general highest incidence rates were found in northern and western Europe and lowest incidence in eastern 
European countries.  This may reflect variation in national breast cancer screening activities between countries.  Irish mortality 
rates were 3rd highest, after Belgium and Denmark and were 22% higher than the EU overall.  However despite this, Irish 
mortality/incidence ratios were the same as that found for the EU overall with 2 deaths for every 10 women diagnosed.  Highest 
mortality/incidence ratios were found in Greece, Latvia and Lithuania and lowest ratios in Finland, Luxembourg and France. 
 
Figure 4d: Estimated cancer incidence and mortality in Europe 2012, female breast cancer 
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Prostate cancer 
Incidence of prostate cancer in Ireland was 4th highest of 27 European countries, after Norway, France and Sweden with rates 
over 50% higher than the EU average (Figure 4e).  Fairly widespread PSA testing and screening in Ireland in recent years 
probably accounts for much of the higher incidence observed here.  Mortality rates in Ireland were comparatively lower, 
although still 17% higher than the EU average and ranked 12th highest overall.  Mortality/incidence ratios in Ireland however 
were second lowest after France, with 1 death for every 10 men diagnosed.  Mortality/incidence ratios tended to be higher in 
eastern Europe with 4 or 5 deaths for every 10 diagnosed cases in Romania, Bulgaria and Greece. 
 
Figure 4e: Estimated cancer incidence and mortality in Europe 2012, prostate cancer 
  
See Appendix III for estimated cancer incidence and mortality for other sites.  
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5.  PREVALENCE  
Follow-up of all registered patients (through matching of registrations to death certificates) is currently complete to the end of 
2010.  From the beginning of 1994 (when national cancer registration commenced) to the end of 2010, a total of 116,081 
females and 125,977 males were diagnosed with cancer (each individual counted once only, regardless of how many cancer 
diagnoses they may have had).  Total prevalence for this 17 year period shows that just over 104,300 of these patients were still 
alive at end 2010, representing 47% of all female and 40% of all male patients (Table 6).  As prevalence takes all patients into 
account, the majority of those still alive are patients diagnosed in recent years.  However prevalence can be a good indicator of 
cancer burden – particularly when shorter time periods are examined; for example 1 year prevalence provides an estimate of 
the number of patients currently undergoing treatment or just recently completing their treatment, 3 year prevalence gives an 
indication of the number of these patients together with those who may have completed treatment but are still under clinical 
surveillance or follow-up. Prevalence for various periods for all cancers as well as for lung, breast, prostate and colorectal 
cancers is listed in Table 6.   
Table 6.  Prevalence of all cancers and the main cancers in Ireland at end 2010 
Prevalence 17 years 10 years 5 years 3 years 1 year 
 diagnosed from  
Jan 1994 
diagnosed from  
Jan 2001 
diagnosed from  
Jan 2006 
diagnosed from  
Jan 2008 
diagnosed during  
2010 
all cancers  
excluding 
NMSC 
total % of all  
patients  
diagnosed 
total % of all  
patients  
diagnosed 
total % of all 
patients 
diagnosed 
total % of all 
patients 
diagnosed 
total % of all 
patients 
diagnosed 
females 54,145 47% 42,144 56% 26,883 65% 18,533 72% 7,228 83% 
males 50,222 40% 42,426 51% 28,369 62% 19,554 68% 8,017 81% 
‡all <65 47,459 71% 39,617 75% 27,119 80% 19,007 84% 7,618 92% 
‡all 65+ 56,908 32% 44,953 42% 28,133 53% 19,080 60% 7,627 74% 
total 104,367 43% 84,570 53% 55,252 64% 38,087 70% 15,245 82% 
                 
LUNG                 
females 1,620 14% 1,446 19% 1,151 27% 937 36% 528 57% 
males 1,878 10% 1,652 15% 1,362 23% 1,165 32% 681 53% 
‡all <65 1,177 27% 1,075 29% 895 35% 746 44% 440 68% 
‡all 65+ 2,321 9% 2,023 13% 1,618 21% 1,356 29% 769 50% 
total 3,498 12% 3,098 16% 2,513 25% 2,102 33% 1,209 55% 
                 
BREAST                 
females 24,236 68% 18,837 79% 11,506 88% 7,690 93% 2,653 98% 
males 147 57% 122 71% 85 83% 59 91% 25 100% 
‡all <65 13,577 83% 11,290 89% 7,350 94% 5,078 97% 1,817 99% 
‡all 65+ 10,806 55% 7,669 68% 4,241 79% 2,671 85% 861 94% 
total 24,383 68% 18,959 79% 11,591 88% 7,749 93% 2,678 98% 
                 
PROSTATE                 
females - -  - - - -  - - - -  
males 21,551 62% 19,393 76% 12,495 87% 8,276 92% 3,061 97% 
‡all <65 5,186 94% 5,094 95% 4,044 97% 2,924 98% 1,202 99% 
‡all 65+ 16,365 56% 14,299 70% 8,451 83% 5,352 88% 1,859 95% 
total 21,551 62% 19,393 76% 12,495 87% 8,276 92% 3,061 97% 
                 
COLORECTAL                 
females 6,222 42% 4,797 52% 3,117 64% 2,125 71% 843 84% 
males 7,805 40% 6,339 51% 4,327 65% 3,015 73% 1,188 86% 
‡all <65 3,991 66% 3,488 71% 2,539 79% 1,780 84% 723 94% 
‡all 65+ 10,036 36% 7,648 46% 4,905 59% 3,360 68% 1,308 81% 
total 14,027 41% 11,136 52% 7,444 64% 5,140 72% 2,031 85% 
‡ refers to age category of patient at end of 2010 
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A total of 1,209 patients diagnosed with lung cancer during 2010 were still alive at the end of that year (1 year prevalence) 
(Table 6).  This represents 55% of all patients diagnosed who are likely to be still undergoing or just completed treatment.  3 year 
prevalence for lung cancer indicated that 2,102 patients (33% of all those diagnosed) were likely to be still undergoing treatment 
or follow-up clinical surveillance for lung cancer at the end of 2010. 
A total of 14,027 colorectal cancer patients, 24,383 breast cancer patients and 21,551 prostate cancer patients diagnosed since 
1994 were still alive at the end of 2010, representing 41%, 68% and 62% of all patients diagnosed during the 17 year period 
respectively.  These cancers all have a better prognosis than lung cancer and just taking those patients who are likely to be still 
under active treatment or clinical follow-up (3 year prevalence), the percentages of all patients diagnosed are higher than those 
observed for lung cancer.  Three year prevalence for colorectal cancer was 5,140 (72% of all patients diagnosed), for breast 
cancer 7,749 (93% of all patients diagnosed) and 8,276 for prostate cancer (92% of all patients diagnosed). 
 
 
The total number of patients in the population at 
the end of 2010 diagnosed with the most 
common cancers since 1994 (17 year prevalence) 
is listed in Table 7.   
Some patients had more than 1 cancer diagnosis 
and these patients are counted once only for 
each cancer type.  The majority of patients in the 
population in 2010 were those diagnosed with 
breast, prostate and colorectal cancers.  Other 
cancers with generally good prognoses, such as 
melanoma, also contributed a large proportion 
of the total.   
Cancers with generally poor survival, such as 
pancreas and oesophagus represented fairly low 
numbers in the prevalent population while there 
were much greater numbers of patients still alive 
who had been diagnosed with comparatively 
rarer cancers with good prognoses, such as 
testis.  Over 70% of living prostate, colorectal 
and bladder cancer patients were over 65 at the 
end of 2010 reflecting their generally older age at diagnosis.  Less than 15% of patients diagnosed with cancers of the testis, 
cervix and Hodgkin’s lymphoma were over 65, also indicative of their much younger age at diagnosis. 
 
 
 
Table 7: 17 year prevalence of most common cancer sites, end 2010 
 females males <65‡ 65+ ‡ Total 
breast 24,236 147 13,577 10,806 24,383 
prostate - 21,551 5,186 16,365 21,551 
colorectal 6,222 7,805 3,991 10,036 14,027 
melanoma 4,241 2,501 3,732 3,010 6,742 
lymphoma* 2,701 2,948 3,411 2,238 5,649 
     Hodgkin's lymphoma 596 705 1,155 146 1,301 
     NHL 2,106 2,244 2,258 2,092 4,350 
lung 1,620 1,878 1,177 2,321 3,498 
bladder 1,034 2,421 852 2,603 3,455 
leukaemia 1,294 1,840 1,723 1,411 3,134 
corpus uteri 3,089 - 1,302 1,787 3,089 
kidney 1,079 1,631 1,281 1,429 2,710 
cervix 2,395 - 2,071 324 2,395 
testis - 2,102 2,044 58 2,102 
mouth & pharynx 669 1,104 973 800 1,773 
ovary 1,746 - 1,021 725 1,746 
stomach 519 881 435 965 1,400 
thyroid 1,009 317 1,037 289 1,326 
brain & CNS 546 614 963 197 1,160 
multiple myeloma 463 574 391 646 1,037 
oesophagus 301 520 302 519 821 
pancreas 236 218 167 287 454 
* 2 patients had both Hodgkin's disease and NHL so totals do not equal that 
shown for all lymphoma 
NHL: non-Hodgkin’s lymphoma 
‡ refers to age category of patient at end of 2010 
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6.  AGE PROFILES OF PATIENTS AT DIAGNOSIS AND DEATH 
 
Less than 15% of all patients were under 50 years of age when diagnosed with invasive cancer (Figure 5).  The proportion of all 
patients aged between 50 and 64, between 65 and 74 and aged over 75 was fairly similar and the median age overall was 66 
years.  The age profile of individual cancer types varied considerably however.  Over two-thirds of patients with cancers of the 
stomach, oesophagus, pancreas, bladder, lung, prostate and colorectum as well as multiple myeloma were diagnosed when 
aged 65 or over.  In contrast patients diagnosed with in situ cervical cancer, invasive testicular cancer and Hodgkin’s lymphoma 
were very young by comparison, with mean ages of 31, 33 and 32 respectively.  62% and 43% of invasive and in situ breast 
cancer patients respectively were aged between 50 and 64 when diagnosed.  This corresponds to the age band at which patients 
can avail of the national breast screening service and a greater proportion of patients was diagnosed in this age group than in 
the other age groups shown.  The median age of these patients at diagnosis was 59 (invasive) and 56 (in situ). 
 
 
 
Figure 5. Age profile of cancer patients at diagnosis: 2008-2010 
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The median age at death from cancer in 2010 was 73 years and almost half of all patients were aged over 75 when they died 
(Figure 6).  Median age at death for patients dying from non-melanoma skin cancer (NMSC) was 82 years, representing the 
oldest group overall, although they comprised just 1% of all cancer deaths (83 NMSC deaths in 2010).  Prostate and bladder 
cancer patients had the next highest median ages at death overall (81 and 79 years respectively) and over two-thirds of these 
patients were aged 75 or older at death.   For the most part, those cancers that were diagnosed at older ages tended to have a 
similar age profile at death and patients with stomach, pancreas and lung cancer had very similar median ages at diagnosis and 
death.  The greatest differences between median ages at diagnosis and death were observed for patients with testicular cancer 
and Hodgkin’s lymphoma.  Although over 92% of all testicular cancer patients were under 50 when diagnosed; only 40% of 
patients were in this age group at death, where the median age was 64.  Similarly for Hodgkin’s lymphoma patients, median age 
at diagnosis was 31 but at death was 71 and 44% of patients were aged over 75 when they died. 
 
 
Figure 6. Age profile of cancer patients at death: 2010 
 
Figures in parentheses indicate median age at death  
NHL: non-Hodgkin’s lymphoma, NMSC: non-melanoma skin cancer 
mortality data provided by the Central Statistics Office (www.cso.ie) 
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Three out of every four deaths in Ireland in 2010 
were caused by cancer or by diseases of the 
circulatory or respiratory systems. Cancer 
accounted for 30% of all deaths and was the 
second most common cause of death overall.   
 
The relative proportion of patients dying from 
cancer varied substantially with patient age and 
sex (Table 8).  Cancer represented 35% of all 
deaths in women aged under 50 but only 15% in 
males of the same age group.  Similarly for patients 
in middle age (50-64 years), cancer represented a 
greater proportion of female deaths (56%) 
compared to males (39%).  For males in this age 
group, diseases of the circulatory system 
represented almost one-third of all deaths, 
compared to 16% of all female deaths.  
 
The relatively greater proportion of cancer deaths among young women compared to men (aged under 50) may be due to the 
fact that many cancers diagnosed in women tend to have a younger age profile than those more commonly diagnosed in men; 
for example cancer of the breast and corpus uteri compared to prostate and lung cancer.  In both sexes, deaths from cancer 
outnumbered deaths from diseases of the circulatory system except in those patients aged over 75 years. 
 
Table 8. Percentage of all deaths in Ireland in 2010 where cause of death  
was cancer or diseases of the circulatory or respiratory systems 
     
 Total deaths Cancer Circulatory Respiratory 
females     
<50 years 815 35% 10% 2% 
50-64 years 1,430 56% 16% 5% 
65-74 years 1,943 50% 24% 9% 
75+ years 9,439 20% 42% 16% 
all ages 13,627 29% 35% 13% 
     
males     
<50 years 1,618 15% 13% 2% 
50-64 years 2,253 39% 32% 5% 
65-74 years 2,952 42% 34% 10% 
75+ years 7,511 27% 39% 15% 
all ages 14,334 30% 34% 11% 
     
both sexes     
<50 years 2,433 22% 12% 2% 
50-64 years 3,683 46% 26% 5% 
65-74 years 4,895 45% 30% 9% 
75+ years 16,950 23% 41% 15% 
all ages 27,961 30% 34% 12% 
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7.  TRENDS 
 
7.1 Incidence and mortality trends: 1994-2010 
 
Since 1994, case numbers of all invasive cancers, excluding non-melanoma skin cancers, have increased by 56% overall (from 
12,099 in 1994 to 18,920 in 2010), representing an annual percentage change (APC) of 3% (2.9% in women and 3.3% in men).  
However much of this increase is due to population growth and ageing, and all-cancer incidence rates have shown a lower, 
although still significant, degree of increase (1.1% in women and 1.2% in men) (Figure 7a, Table 9). Although the number of all-
cancer deaths has also increased during this time (from 7,433 in 1994 to 8,316 in 2010), mortality rates have declined, 
significantly so for both sexes, with an annual percentage decline of 1% in females and 1.4% in males.  This has resulted in all-
cancer mortality/incidence ratios declining from 0.6 (6 deaths for every 10 incident cases) in 1994 to 0.4 (4 deaths for every 10 
cases) in 2010 for both males and females. 
 
Figure 7a.  Time trends in incidence and mortality rate (European age standardised) 1994-2010: all invasive cancers, excluding 
non-melanoma skin cancer 
 
Mortality data provided by the Central Statistics Office (www.cso.ie) 
 
Trends in incidence and mortality for both males and females are illustrated for the main 4 cancers (colorectal, lung, female 
breast and prostate) as well as for cervix and melanoma in Figure 7(b-g). Details of these observed trends (annual percentage 
change) are listed in Table 9.  Additional graphs showing trends for other cancers listed in Table 9 are shown in Appendix IV. 
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Table 9. Time trends-annual percentage change (APC) in age standardised rate (ASR) of incidence and mortality 
 FEMALES MALES 
 INCIDENCE   MORTALITY   INCIDENCE   MORTALITY   
 period APC trend period APC trend period APC trend period APC trend 
all invasive-excluding NMSC [1994-2010] 1.1 ↑ [1994-2010] -1.0 ↓ [1994-2010] 1.2 ↑ [1994-2010] -1.4 ↓ 
             
mouth & pharynx [1994-2008] 1.1 ↔ [1994-2010] -1.6 ↓ [1994-2001] -4.1 ↓ [1994-2010] -2.6 ↓ 
 [2008-2010] 23.3 ↔    [2001-2010] 2.4 ↑    
oesophagus [1994-2010] -1.0 ↓ [1994-2010] -1.9 ↓ [1994-2010] 0.3 ↔ [1994-2010] -0.8 ↓ 
             
stomach [1994-2010] -1.6 ↓ [1994-2010] -3.3 ↓ [1994-2003] -3.0 ↓ [1994-2010] -3.4 ↓ 
       [2003-2010] 0.3 ↔    
colorectal [1994-2010] 0.2 ↔ [1994-2010] -2.1 ↓ [1994-2010] 0.3 ↑ [1994-2010] -1.7 ↓ 
             
pancreas [1994-2010] 0.6 ↔ [1994-2010] 0.5 ↔ [1994-2010] 0.8 ↔ [1994-2005] -1.5 ↓ 
          [2005-2010] 3.6 ↔ 
lung [1994-2010] 2.2 ↑ [1994-2010] 0.5 ↑ [1994-2010] -0.7 ↓ [1994-2010] -1.9 ↓ 
             
melanoma-skin [1994-2010] 2.9 ↑ [1994-2010] 1.8 ↔ [1994-2010] 5.1 ↑ [1994-2010] 6.0 ↑ 
             
non-melanoma skin [1994-2000] -0.9 ↔    [1994-2001] -1.9 ↓    
 [2000-2010] 2.5 ↑    [2001-2010] 3.3 ↑    
breast [1994-2010] 1.9 ↑ [1994-2010] -1.9 ↓       
             
cervix [1994-2010] 2.1 ↑ [1994-2010] -0.6 ↔       
             
corpus uteri [1994-2010] 2.4 ↑ [1994-2010] 2.0 ↑       
             
ovary [1994-2010] -0.7 ↔ [1994-2010] -0.5 ↔       
             
prostate       [1994-2004] 7.6 ↑ [1994-2001] -0.1 ↔ 
       [2004-2010] 1.4 ↔ [2001-2010] -2.8 ↓ 
testis       [1994-2010] 3.2 ↑ [1994-2010] -4.5 ↓ 
             
kidney [1994-2010] 3.3 ↑ [1994-2010] 0.6 ↔ [1994-2010] 2.9 ↑ [1994-2010] 1.1 ↔ 
             
bladder [1994-2010] -2.1 ↓ [1994-2010] -0.7 ↔ [1994-2010] -2.6 ↓ [1994-2010] -1.2 ↓ 
             
brain-spinal cord [1994-2010] 0.6 ↔ [1994-2010] -1.1 ↔ [1994-2008] 0.4 ↔ [1994-2010] -0.4 ↔ 
       [2008-2010] -7.7 ↔    
thyroid [1994-2010] 6.9 ↑ [1994-2010] -4.7 ↓ [1994-2010] 5.1 ↑ [1994-2010] -0.3 ↔ 
             
lymphoma (total) [1994-2010] 1.7 ↑ [1994-2010] -1.4 ↔ [1994-2010] 1.7 ↑ [1994-2010] -1.1 ↓ 
             
Hodgkin's lymphoma [1994-2010] 1.8 ↑ [1994-2010] -2.9 ↔ [1994-2010] 1.9 ↑ [1994-2010] -5.4 ↓ 
             
non-Hodgkin’s lymphoma [1994-2010] 1.6 ↑ [1994-2000] 4.2 ↔ [1994-2010] 1.7 ↑ [1994-2010] -0.6 ↔ 
    [2000-2010] -3.6 ↓       
multiple myeloma [1994-2010] 0.3 ↔ [1994-2010] -2.0 ↓ [1994-2010] 0.0 ↔ [1994-2008] -1.2 ↓ 
          [2008-2010] -15.0 ↓ 
leukaemia [1994-2010] 0.0 ↔ [1994-2001] 3.1 ↔ [1994-2004] 3.1 ↑ [1994-2004] 2.9 ↑ 
    [2001-2010] -4.2 ↓ [2004-2010] -4.5 ↓ [2004-2010] -7.2 ↓ 
in situ breast [1994-2010] 9.9 ↑          
             
in situ cervix [1994-2010] 6.8 ↑          
             
APC: ↑=significant increase, ↓=significant decrease, ↔=change was not significant, at the 95% level 
APC was calculated using Joinpoint program (2; 3) 
Mortality data provided by the Central Statistics Office (www.cso.ie) 
 
 
 
 
 Cancer in Ireland 2013: Annual report Page  22 
 
 
Similar to all cancers, colorectal cancer 
incidence rates have increased since 1994, 
although at a lower level (APC 0.2% for females, 
0.3% for males) (Figure 7b, Table 9).   
However, mortality rates have declined 
significantly for both sexes, resulting in a 
reduction in mortality/incidence ratios from 0.5 
(5 deaths for every 10 cases) to 0.4 (4 deaths for 
every 10 cases) for both males and females. 
 
 
 
 
 
 
 
 
 
Lung cancer trends showed very different 
patterns between males and females (Figure 
7c).  Although incidence and mortality rates in 
males have been higher than in females 
throughout 1994 to 2010, this difference has 
declined over time.  While both incidence and 
mortality rates in males have declined 
significantly since 1994, lung cancer incidence in 
females has increased substantially, with a 
statistically significant APC of 2.2% (compared 
to -0.7% in males) (Table 9).   
Female lung cancer mortality rates have also 
increased significantly by 0.5% annually.  In 
contrast, male mortality rates have fallen 
significantly by 1.9% per year. 
 
 
 
 
 
 
 
Figure 7b.  Time trends in incidence and mortality rate  
(European age standardised) 1994-2010: colorectal cancer 
 
Figure 7c.  Time trends in incidence and mortality rate  
(European age standardised) 1994-2010: lung cancer 
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Although female breast cancer has increased significantly in 
incidence since 1994, mortality rates have declined, also significantly 
and by the same factor (APC 1.9%) (Figure 7d, Table 9).  As a result 
mortality/incidence ratios have fallen from 0.4 (4 deaths for every 10 
cases) to 0.2 (2 deaths for every 10 cases).   
 
The influence of screening is evident from the increases in incidence 
rates observed from 2000 to 2002 and again from 2006 to 2008 
corresponding to the periods when BreastCheck, the national 
screening programme, commenced screening in the eastern part of 
the country and then extended on a national level. 
 
 
 
 
 
 
 
 
 
The result of diagnostic testing is evident when looking at the trends 
in prostate cancer incidence, which reached a peak in 2004 (Figure 
7e).  Incidence increased annually (and significantly) by 7.6% up to 
2004, consistent with increases in PSA testing.  Since 2004, although 
incidence has continued to increase, it is at a lower rate (1.4% per 
year) and the trend is not significant (Table 9).   
Prostate cancer mortality rates have declined since 1994, particularly 
since 2001 with an APC of -2.8%.  Similar to female breast cancer, 
mortality/incidence ratios have fallen from 0.4 in 1994 to 0.2 in 2010. 
 
 
 
 
 
 
 
 
Figure 7d.  Time trends in incidence and mortality rate   
(European age standardised) 1994-2010 
female breast cancer 
 
Figure 7e.  Time trends in incidence and mortality rate   
(European age standardised) 1994-2010 
 prostate cancer 
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Screening activity has also had an impact on cervical cancer incidence; case numbers of invasive tumours increasing from 176 in 
1994 to 310 in 2010 (equivalent to an annual percentage increase in incidence rate of 2.1%) (Table 9, Figure 7f).  The number of 
in situ (CIN III) cancers diagnosed per year increased considerably during this time, from 717 cases in 1994 to 2,618 in 2010, an 
overall increase in case numbers of 265% or an annual percentage increase in incidence rate of 6.8%.   
An annual average of 78 deaths from cervical cancer has occurred since 1994 and although mortality rates have declined 
somewhat, this was not statistically significant and mortality/incidence ratios have remained the same at 0.3 (3 deaths for every 
10 incident cases). 
 
Figure 7f.  Time trends in incidence and mortality rate (European age standardised) 1994-2010: invasive and in situ cervix 
invasive in situ 
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In 1994, incidence of melanoma was 56% higher in females than in males.  Although incidence has increased significantly in both 
sexes over time, greater increases in males (APC in males 5.1% compared to 2.9% in females) have resulted in a decline in the 
difference between the sexes and female rates in 2010 were 28% higher than males (Table 9, Figure 7g).  Mortality rates in 
males have also increased significantly, with an APC of 6%.  Female mortality rates have also increased somewhat, although not 
significantly.  Despite these changes, mortality/incidence ratios have remained the same over time for both sexes; 0.1 in females 
and 0.2 in males. 
 
Figure 7g.  Time trends in incidence and mortality rate (European age standardised) 1994-2010: melanoma skin cancer 
 
See appendix IV for time trends for other major sites 
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7.2 Long term mortality trends: 1950-2010 
 
Data on cancer mortality is available from the early 1950’s (provided by the Central Statistics Office, www.cso.ie).  Mortality 
rates for all cancer deaths in both sexes increased gradually from the early 1950’s to 1990’s but have shown a clear decline 
during the last 2 decades (Figure 8, Table 10). Greater increases in male mortality rates compared to females between 1950 and 
the early 1990’s, resulted in an initial divergence in mortality curves between the sexes. However subsequent greater decreases 
in male mortality rates compared to females have resulted in a decline in this difference.  Male mortality rates are currently 
approximately 35% higher than females. 
Figure 8.  Trends in mortality: age standardised rate (ASR), 1950-2010: all cancer deaths 
 
 
Table 10.  Annual percentage change (APC) in age standardised rate (ASR) mortality: 1950-2010 
 FEMALES MALES 
site Period APC trend Period APC trend 
       all cancer deaths  [1950-1974] 0.7 ↑ [1950-1976] 1.2 ↑ 
 [1974-1991] 0.1 ↔ [1976-1993] 0.6 ↑ 
 [1991-2010] -1.0 ↓ [1993-2010] -1.5 ↓ 
       lung [1950-1971] 15.0 ↑ [1950-1966] 17.6 ↑ 
 [1971-2010] 1.1 ↑ [1966-1984] 2.6 ↑ 
    [1984-2010] -1.9 ↓ 
       colorectal [1950-1976] 0.7 ↑ [1950-1961] -0.9 ↔ 
 [1976-2010] -2.0 ↓ [1961-1988] 0.8 ↑ 
    [1988-2010] -1.4 ↓ 
       breast [1950-1989] 1.2 ↑ - - - 
 [1989-2010] -1.8 ↓ - - - 
       prostate    [1950-1969] 3.1 ↑ 
    [1969-1998] 1.7 ↑ 
    [1998-2010] -2.3 ↓ 
APC: ↑=significant increase, ↓=significant decrease, ↔=change was not significant, at the 95% level 
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Much of the increase in all cancer mortality rates 
over time was due to lung cancer deaths, and 
annual percentage change in mortality rates for 
this cancer alone was 15% in females and 17.6% 
in males  between 1950 and the mid 1960’s-early 
1970’s (Table 10). Mortality rates for males 
reached a peak in the early 1980’s with 
approximately 78 deaths per 100,000 per year 
(Figure 9a).   At this time, lung cancer 
represented approximately 30% of all cancer 
deaths in males (Figure 9b).  However mortality 
rates in males have declined subsequently, by 
almost 2% per year, and current mortality rates 
are 46 deaths per 100,000 per year.  Lung cancer 
now represents 22% of all cancer deaths in 
males.   
 
 
 
In contrast, female lung cancer mortality rates 
have shown a slower increase over time (Figure 
9a) but unlike males, mortality rates have 
continued to increase over time and reached 28 
deaths per 100,000 in 2010. Lung cancer deaths 
now represent 18% of all female cancer deaths, 
compared to less than 5% in the late 1950’s early 
1960’s (Figure 9b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9a.   Time trends in mortality: age standardised rate (ASR) 
  1950-2010: lung cancer 
 
 
Figure 9b. Percentage of cancer deaths attributable to lung  
cancer:1955-2010 
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Between 1950 and the mid 1980’s, colorectal cancer 
mortality rates were variable, particularly in males (Figure 
10).  After an initial decline, male mortality rates 
subsequently increased to a peak of 40 deaths per 100,000 
in the mid 1970’s.  Following a period of generally lower 
but fluctuating mortality from the late 1970’s to late 
1980’s, male mortality rates have declined significantly 
over the last 20 years or so (Table 10) and current rates 
are approximately 25 deaths per 100,000 per year.   
Mortality rates in females were on average 18% lower 
than males between 1950 and the mid 1970’s and reached 
a peak of 32 deaths per 100,000 in 1975.  Female mortality 
rates declined significantly from 1976 to 2010 (APC -2.0%), 
and currently at 15 deaths per 100,000 per year, are 67% 
lower than male mortality rates. 
 
Female breast and prostate cancer mortality rates have shown similar patterns in long term mortality (Figure 11 a & b).  
Mortality rates for both cancers increased significantly from 1950, reaching a peak of 42 breast cancer deaths per 100,000 per 
year in 1989 and 34 prostate cancer deaths per 100,000 per year in the mid 1990’s.  Mortality rates for both have declined 
significantly in recent years (Table 10).  Current female breast cancer mortality rates are close to those values observed in the 
early 1950’s (27 deaths per 100,000 per year).  Current mortality rates for prostate cancer are similar, at 25 deaths per 100,000 
per year, but are still substantially higher than those observed in the 1950’s and 1960’s. 
 
Figure 11.  Time trends in mortality: age standardised rate (ASR) 1950-2010: female breast cancer and prostate cancer 
(a) female breast (b) prostate 
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Figure 10.   Time trends in mortality: age standardised rate (ASR) 
  1950-2010: colorectal cancer 
 
Mortality data provided by the Central Statistics Office  
(www.cso.ie) 
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8.  TREATMENT 
 
8.1 Treatment summary  
 
During the period 2005-2009, 50% of all invasive 
cancers (excluding non-melanoma skin) had 
tumour-directed surgery, 31% chemotherapy, 
33% radiotherapy and 23% no tumour-directed 
treatment.  However the proportion of cases that 
received each treatment varied considerably by 
cancer type (Table 11).   
As expected, rates of tumour-directed surgery 
were highest for solid tumours; over 75% of 
patients with cancers of the colorectum, breast, 
corpus uteri, testis and thyroid as well as 
melanoma underwent surgery to either 
completely remove or reduce the tumour.  Rates 
of surgery were low for cancers such as pancreas, 
lung and oesophagus where either the site of the 
tumour can prove difficult for surgery or patients 
frequently present with already late stage 
cancers.    
 
Chemotherapy rates were highest for cancers of 
the blood and lymphatic systems but also for 
cancers of the rectum, breast and ovary.  Highest 
rates of radiotherapy were found for cancers of 
the mouth & pharynx, breast, cervix and brain & CNS.  Just over 40% of rectal cancer patients had radiotherapy compared to 
only 3.5% of those with colon cancer.  Chemotherapy was also more frequent in rectal than in colon cancer patients.  A 
substantial proportion of patients had no cancer-directed treatment, although many of these patients had other procedures, 
such as palliative treatment to relieve symptoms.  Over 60% of pancreatic cancer patients had no tumour directed therapy.  
Watchful waiting for some cancers may result in apparently high percentages of untreated cases, as was the case for leukaemia, 
where overall 54% were classed as untreated.  Over two-thirds of these untreated cases were chronic lymphocytic subtypes 
where watchful waiting is a recognized management.  Watchful waiting is also a common management for prostate cancers and 
22% of these patients were also classified as untreated.  Hormonal therapy (not shown in Table 11) was only administered to 
substantial numbers of patients with breast and prostate cancer, where 52% and 35% were treated respectively.  In addition 
12% of myeloma patients and 5% of patients with brain & CNS tumours had hormonal therapy.  It should be noted that 
Table 11: Percent of patients that received tumour-directed  surgery, 
chemotherapy, radiotherapy and no-tumour directed therapy for  
the most common cancer sites, 2005-2009 inclusive 
      
 all cases surgery chemotherapy radiotherapy no treatment 
mouth & pharynx 1,533 57.9% 33.3% 63.9% 11.4% 
oesophagus 1,820 25.8% 41.5% 44.8% 30.2% 
stomach 2,471 40.6% 35.0% 13.8% 37.8% 
colorectal 11,384 77.4% 42.5% 17.1% 13.7% 
colon 7,285 79.4% 38.1% 3.5% 14.4% 
rectum 3,912 75.1% 50.4% 40.2% 12.2% 
pancreas 2,308 13.0% 31.1% 9.8% 61.1% 
lung 9,816 15.8% 33.8% 39.8% 36.8% 
melanoma 3,493 93.7% 5.7% 3.6% 4.9% 
breast 12,642 85.3% 49.7% 65.6% 4.5% 
cervix 1,400 63.6% 41.4% 54.9% 5.3% 
corpus uteri 1,698 93.8% 12.4% 44.8% 4.1% 
ovary 1,710 67.3% 59.4% 2.7% 20.6% 
prostate 13,612 27.0% 1.6% 41.1% 22.0% 
testis 862 97.0% 37.1% 28.3% 1.5% 
kidney 2,198 66.7% 14.9% 10.1% 23.8% 
bladder 2,299 73.8% 21.9% 15.1% 20.1% 
brain & CNS* 1,642 51.2% 24.7% 55.2% 26.6% 
thyroid 727 88.7% 2.6% 45.3% 8.1% 
Hodgkin's lymphoma 565 20.5% 82.8% 26.5% 9.6% 
NHL‡ 3,015 19.3% 65.3% 17.2% 23.3% 
multiple myeloma 1,196 2.2% 65.6% 26.6% 25.2% 
leukaemia 2,379 1.1% 44.1% 2.6% 54.2% 
all invasive cancers 86,434 49.9% 31.2% 33.1% 22.8% 
NHL‡: non-Hodgkin’s lymphoma,  CNS*: central nervous system  
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hormonal therapy is sometimes administered at outpatient level and it is possible that some patients that did not have 
hormonal therapy as a first line, inpatient procedure may not be registered.  For this reason, the figures quoted on hormonal 
therapy should be regarded as conservative estimates only. 
8.2 Treatment of cancer by age and sex 
 
Figures 12-15 show details of treatments 
received by sex and age group for the 4 
most commonly diagnosed cancers 
between 2005 and 2009 inclusive.  For all 
four sites, there was a clear drop in 
treatment rates for patients aged 75 and 
over. For patients with colorectal cancer, 
31% of females and 25% of males aged 75 
years or older had no tumour directed 
therapy (compared to 17% and 14% 
overall respectively) (Figure 12). Rates of 
surgery, radiotherapy and particularly 
chemotherapy were lower in this age 
group compared to younger patients.  
Males were more likely than females to 
have chemotherapy and radiotherapy (the 
latter for rectal cancers only) for all age 
groups. As already indicated, rates of 
surgery were low for lung cancer patients, 
but were highest in those patients aged 
under 65 (Figure 13). Slightly more 
females than males in this age group 
underwent surgery.  There was little 
difference between the sexes in terms of 
the relative proportion of patients having 
chemotherapy or radiotherapy but as seen 
for colorectal cancers, a much higher 
proportion of elderly patients (aged 75 or 
over) had no treatment compared to 
other age groups (64% of females and 62% 
of males were untreated compared to 
approximately 40% overall). 
 
Figure 12.  Percentage of colorectal patients who received each treatment 
category: 2005-2009 
  
  
*refers to patients with rectal cancer only  
Figure 13.   Percentage of lung cancer patients who received each treatment 
category:  2005-2009 
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Although overall rates of tumour-
directed surgery were high for breast 
cancer patients compared to some 
other sites, only half of those patients in 
the oldest age group had surgery  
(Figure 14).  
Similar to the pattern seen for colorectal 
and lung cancer patients, there was a 
drop in the relative proportion of 
patients having chemotherapy and 
radiotherapy with age.  However 
hormonal therapy was more frequent in 
the older women, with 57% treated 
compared to 46% in the youngest age 
group or 50% overall.  Despite this 
however, almost 1 in 5 women aged 
over 75 had no tumour directed 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Percentage of female breast cancer patients who received  
each treatment category: 2005-2009 
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Overall rates of surgery for prostate 
cancer were low, as indicated in Table 
11.  However, the chance of having had 
surgery was greatest for those men 
aged under 65 (Figure 15).   
Unlike the other 3 cancer sites, the rate 
of surgery was similar in patients aged 
65-74 and in 75+ year olds.  Rates of 
radiotherapy were highest in men aged 
65-74 (46%) but only 11% of men in the 
oldest age group had radiotherapy.   
 
 
Similar to female breast cancer patients, hormonal therapy was highest in the older patients where almost half of all men aged 
75 or over were treated.  Chemotherapy is not normally recommended for prostate cancer and less than 3% of all patients 
diagnosed between 2005 and 2009 had chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 15.  Percentage of prostate cancer patients who received each treatment 
category: 2005-2009 
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8.3 Trends in treatment 
 
Overall rates of surgery for all cancers combined increased from 48% in 2000-2004 to 50% in 2005-2009 and increases in the 
rate of surgery were observed for most individual cancer types between these time periods (Figure 16a).  However this varied 
considerably between cancers.  The greatest relative increase in the proportion of patients undergoing surgery was observed for 
Hodgkin’s lymphoma (11% to 21%) and pancreatic cancer patients (8% to 13%).  Substantially more lung and oesophageal cancer 
patients also had surgery in 2005-2009 compared to 2000-2004.  However a decline in the rate of surgery was observed for 
some sites, with a 21% reduction in the proportion of prostate cancer patients having had surgery between the 2 time periods. 
 
The rate of chemotherapy increased overall by 13% between 2000-2004 and 2005-2009 but like surgery, this also varied 
between cancers (Figure 16b).  Relative increases of between 60% and 75% were observed in patients with cancers of the mouth 
& pharynx, pancreas, brain & CNS, bladder, kidney and corpus uteri.  Chemotherapy declined somewhat in leukaemia patients 
over time with the percentage of patients having had chemotherapy falling from 46% to 44% between the two time periods. 
 
Rates of radiotherapy were more variable than those observed for surgery and chemotherapy.  Overall rates of radiotherapy 
increased from 29% in 2000-2004 to 33% in 2005-2009 (all cancers combined).  However the relative proportion of patients 
having radiotherapy declined in the case of testicular cancer and Hodgkin’s lymphoma (Figure 16c).  Greatest relative increases 
in the proportion of patients treated were observed for prostate, bladder and thyroid cancers. 
 
Although the proportion of patients that had no tumour-directed therapy dropped from 27% to 23% overall, there was an 
increase in the percentage of untreated patients in the case of leukaemia (from 52% to 54%) and Hodgkin’s lymphoma (from 6% 
to 10%) (Figure 16d).  A decline of between 10% and 25% of all patients having no treatment was observed for most cancer sites, 
with greatest relative change observed for colon, melanoma and thyroid.  Two sites which have showed some of the greatest 
changes in terms of the relative proportion of patients treated over time; lung and pancreas, both showed a substantial drop in 
the number of patients untreated overall with 17% and 19% fewer patients untreated in 2005-2009 compared to 2000-2004. 
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Figure 16. Percentage of cancers that received tumour-directed surgery, chemotherapy, radiotherapy or no treatment 
2000-2004 & 2005-2009 
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9.  SURVIVAL  
Observed survival is simply the proportion of patients remaining alive after a given period of time. Relative survival (RS) is the 
ratio of the observed survival proportion for a given group of cancer cases to the expected survival proportion of a group of 
individuals with the same demographic attributes. In practice, relative survival is similar to cause-specific survival—it measures 
the excess mortality due specifically to the cancer, and so is always greater than observed survival.  Relative survival is now used 
by most cancer registries in place of cause specific survival because the actual cause of death in any given cancer case is not 
always known. Relative survival also facilitates international comparison, as it reduces problems related to international 
inconsistency in coding cause of death.  
 
Five year relative survival for all cancer 
patients diagnosed between 2005 and 2009 
was 60.0% for males and 61.5% for females 
(Figure 17).  
 
Cancers of the testis, prostate and thyroid 
had the best survival rates and 5 year 
survival for testicular cancer patients was 
98%.  Poorest survival rates were observed 
for patients diagnosed with cancer of the 
pancreas (5% in males, 8% in females) and 
also for liver, lung, oesophagus, brain and 
stomach, all with 5 year survival rates of less 
than 22%.   
 
Females tended to have better survival rates 
than males for most cancers, and this was 
statistically significant in the case of 
melanoma and for cancers of the head & 
neck and lung.  However males tended to 
have better survival rates, although not 
statistically significantly so, in the case of 
leukaemia and for cancers of the bone and 
cartilage and bladder. 
 
 
 
 
 
Figure 17. Five year relative survival for cancers diagnosed in men and women: 
2005-2009 
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There have been large and statistically 
significant improvements in survival rates for 
both males and females over time (Figure 18).  
For all invasive cancers combined, five year 
survival in females has improved from 52% in 
1994-1999 to 61.5% in 2005-2009.   
 
However greater improvements have been 
observed in males where 5 year relative 
survival was just 42% in 1994-1999, 20% lower 
than that in females.  Male survival rates 
increased to 60% in 2005-2009, resulting in an 
almost equalization in overall cancer survival 
rates between the sexes. 
 
Figure 19 (a-h) illustrates how 5 year relative survival has changed over time for a number of cancers; those with broadly similar 
survival rates are grouped together for convenience.  Almost all cancers showed continuous improvements in survival rates from 
1994-1999 to 2000-2004 and on to 2005-2009.  Patients diagnosed with non-Hodgkin’s lymphoma (Figure 19f), colorectal (Figure 
19d), female breast (Figure 19g) and prostate cancers (Figure 19h) all had significantly improved survival rates from one period 
to the next.  Prostate cancer survival improved considerably, from 69% to 87%, between 1994-1999 and 2000-2004, probably 
reflecting the impact of screening activity and increased detection of early stage cancers.   
 
Most cancers showed greatest improvements in survival rates between 1994-1999 and 2000-2004 with a lower degree of 
increase in later years.  Patients with testicular cancer (Figure 19h), leukaemia (Figure 19d) and Hodgkin’s lymphoma (Figure 19f) 
all showed significant improvements in survival from 1994-1999 to 2000-2004 and although survival rates continued to improve 
for testicular cancer and leukaemia patients in 2005-2009, this was not statistically significant.  Survival rates dropped in the 
case of Hodgkin’s lymphoma from 2000-2004 to 2005-2009 (from 86% to 83%), although this was not statistically significant. 
 
Other cancers, notably multiple myeloma (Figure 19c), lung (Figure 19a), kidney (Figure 19d) and thyroid (Figure 19g) showed 
greatest and statistically significant improvements in survival between 2000-2004 and 2005-2009.  Although survival for these 
cancers had also improved from 1994-1999, this was comparatively lower and not significant. 
 
There was very little change over time in the relative survival for brain cancers (Figure 19b), where survival has remained under 
20%.  Similarly for cancer of the corpus uteri (Figure 19e), although having a much better prognosis than brain cancer, survival 
has also remained fairly static, at between 77% and 78%.  Melanoma, one of the cancers with the best overall survival rate, also 
showed relatively little change over time (improving from 84% to 86% overall) (Figure 19g).  Bladder cancer, which also showed 
little change in survival rate between 1994-1999 and 2000-2004, had a statistically significant drop in survival in 2005-2009 
(from 71% to 63%, Figure 19e).  The reasons for this are unclear but may be indicative of some uncertainty in tumour 
classification and coding for bladder cancers, which has been noted in the literature. 
Figure 18. Five year relative survival for males and females diagnosed with  
all invasive cancers during the periods 1994-1999, 2000-2004 and 2005-2009 
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Figure 19 (a-h).  
Five year relative survival for various cancers diagnosed during the periods 1994-1999, 2000-2004 and 2005-2009 
a. b. 
  
c. d. 
  
e. f. 
  
g. h. 
  
Key: NHL*:non-Hodgkin’s lymphoma, breast*: females only bars indicate 95% confidence interval 
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METHODS  
 
The National Cancer Registry (NCR) records demographic, clinical and treatment information for all cancers diagnosed in Ireland 
according to internationally accepted registration and coding conventions. [http://www.ncri.ie]  Completeness of case 
ascertainment at five years after diagnosis is estimated to be at least 98%. (4) 
Mortality data was provided by the Central Statistics Office [http://www.cso.ie].  National anonymised datasets for all cancer 
deaths are provided to the Registry annually by the CSO.  In addition, long term mortality data (dating from 1950) was provided 
by the CSO for a number of principal cancer sites.  For survival analysis, follow-up of all diagnosed cases is achieved through 
matching of cancer registrations to death certificate information, also provided by the CSO. 
The age standardised (ASR) rate is the proportion of cases (or deaths) in a given population (and year) weighted by the age 
structure of the population. Age standardised rates (ASR) for incidence and mortality were weighted by the European standard 
population. (5) In order to discern whether there was actually a trend over time, or whether the changes were due to random 
variation, we examined trends in incidence and mortality rates for various cancer sites, from 1994-2010 for incidence, and from 
1950-2010 for mortality. Annual percentage change (APC) of incidence and mortality over time was estimated using the 
Joinpoint regression program. (2; 3)   
For international comparisons of incidence and mortality we consulted the European Cancer Observatory (ECO) website.  The 
ECO is a project developed at the International Agency for Research on Cancer (IARC) in partnership with the European Network 
of Cancer Registries (ENCR) which is supported by the European Commission. (1) 
Survival to five years was presented for the major cancer sites as relative survival (RS); the ratio of observed survival among a 
group of cases to the expected survival among the general population of the same age, sex and country. Relative survival was 
estimated using the ‘strs’ command in STATA 11.0 according to a method described in Dickman et al. (6) To visualise trends in 
survival, relative survival to five years was presented for the major cancer sites for three diagnostic periods; 1994-1999, 2000-
2004 and 2005-2009  
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APPENDIX I: SUMMARY TABLE - CANCER INCIDENCE 2008-2010 
 
ICD10 cancer site  
(INCIDENCE 2008-2010) 
FEMALES MALES TOTAL 
‡all invasive cancers minus NMSC (C44) 
C00-C43, C45-C96 
†ASR/100,000 
*cumulative risk (%) to age 75 years  
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
C00: lip 4 0.04% 0.02% 0.15 0.01 16 0.16% 0.10% 0.81 0.06 20 0.11% 0.06% 0.44 0.04 
C01: base of tongue 6 0.07% 0.04% 0.29 0.03 20 0.20% 0.13% 1.01 0.10 26 0.14% 0.08% 0.64 0.06 
C02: other tongue 29 0.33% 0.17% 1.27 0.10 34 0.35% 0.22% 1.68 0.15 63 0.34% 0.19% 1.46 0.13 
C03: gum 8 0.09% 0.05% 0.31 0.03 10 0.10% 0.06% 0.50 0.04 18 0.10% 0.06% 0.41 0.03 
C04: floor of mouth 9 0.10% 0.05% 0.40 0.04 18 0.18% 0.11% 0.89 0.08 27 0.14% 0.08% 0.64 0.06 
C05: palate 9 0.10% 0.05% 0.39 0.03 13 0.14% 0.09% 0.65 0.06 22 0.12% 0.07% 0.52 0.05 
C06: other mouth 13 0.15% 0.08% 0.56 0.04 14 0.14% 0.09% 0.68 0.06 27 0.15% 0.08% 0.62 0.05 
C07: parotid 12 0.14% 0.07% 0.50 0.04 18 0.18% 0.12% 0.88 0.06 30 0.16% 0.09% 0.66 0.05 
C08: other salivary 4 0.05% 0.02% 0.17 0.01 4 0.04% 0.03% 0.21 0.02 8 0.04% 0.02% 0.19 0.02 
C09: tonsil 12 0.13% 0.07% 0.54 0.05 31 0.32% 0.20% 1.53 0.13 43 0.23% 0.13% 1.02 0.09 
C10: oropharynx 3 0.03% 0.02% 0.14 0.01 9 0.09% 0.06% 0.44 0.04 12 0.06% 0.04% 0.29 0.03 
C11: nasopharynx 4 0.05% 0.02% 0.19 0.01 13 0.13% 0.08% 0.63 0.06 17 0.09% 0.05% 0.41 0.04 
C12: pyriform 4 0.04% 0.02% 0.15 0.01 18 0.19% 0.12% 0.90 0.09 22 0.12% 0.07% 0.52 0.05 
C13: hypopharynx 4 0.05% 0.03% 0.18 0.02 13 0.13% 0.08% 0.63 0.06 17 0.09% 0.05% 0.40 0.04 
C14: other mouth/pharynx 3 0.03% 0.02% 0.10 0.01 12 0.12% 0.07% 0.58 0.05 15 0.08% 0.04% 0.33 0.03 
C01-C14: mouth and pharynx 119 1.36% 0.70% 5.18 0.43 227 2.32% 1.46% 11.22 0.99 346 1.87% 1.07% 8.11 0.71 
C15: oesophagus 130 1.48% 0.77% 5.17 0.40 242 2.47% 1.55% 11.9 0.97 372 2.00% 1.14% 8.37 0.69 
C16: stomach 191 2.18% 1.13% 7.60 0.56 332 3.38% 2.13% 16.25 1.24 523 2.82% 1.61% 11.56 0.90 
C17: small intestine 24 0.27% 0.14% 1.01 0.08 37 0.37% 0.24% 1.78 0.15 61 0.33% 0.19% 1.38 0.12 
C18: colon 692 7.90% 4.09% 28.2 2.22 839 8.55% 5.38% 41.35 3.16 1,531 8.24% 4.71% 34.11 2.69 
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ICD10 cancer site  
(INCIDENCE 2008-2010) 
FEMALES MALES TOTAL 
‡all invasive cancers minus NMSC (C44) 
C00-C43, C45-C96 
†ASR/100,000 
*cumulative risk (%) to age 75 years  
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
C19: rectosigmoid 70 0.80% 0.41% 2.89 0.22 111 1.13% 0.71% 5.44 0.43 181 0.97% 0.56% 4.06 0.32 
C20: rectum 207 2.36% 1.22% 8.73 0.72 419 4.27% 2.69% 20.61 1.65 626 3.37% 1.93% 14.27 1.18 
C21: anus 29 0.33% 0.17% 1.23 0.10 21 0.21% 0.13% 1.02 0.07 50 0.27% 0.15% 1.11 0.08 
C18-C21: colorectal 998 11.39% 5.91% 41.05 3.23 1,389 14.16% 8.91% 68.42 5.24 2,387 12.86% 7.35% 53.56 4.23 
C22: liver 62 0.70% 0.36% 2.46 0.18 133 1.36% 0.85% 6.54 0.54 195 1.05% 0.60% 4.42 0.36 
C23: gallbladder 31 0.35% 0.18% 1.26 0.10 12 0.13% 0.08% 0.62 0.04 43 0.23% 0.13% 0.96 0.07 
C24: other biliary 41 0.47% 0.24% 1.53 0.11 53 0.54% 0.34% 2.60 0.17 94 0.51% 0.29% 2.01 0.14 
C25: pancreas 227 2.59% 1.34% 8.99 0.67 248 2.53% 1.59% 12.38 0.96 475 2.56% 1.46% 10.59 0.82 
C26: other digestive 19 0.21% 0.11% 0.70 0.05 17 0.17% 0.11% 0.82 0.06 36 0.19% 0.11% 0.76 0.05 
C30: nasal cavity/middle ear 8 0.09% 0.05% 0.32 0.02 8 0.08% 0.05% 0.36 0.03 16 0.08% 0.05% 0.34 0.03 
C31: sinuses 2 0.03% 0.01% 0.09 0.01 9 0.09% 0.06% 0.40 0.03 11 0.06% 0.03% 0.24 0.02 
C32: larynx 20 0.22% 0.12% 0.87 0.07 132 1.35% 0.85% 6.55 0.58 152 0.82% 0.47% 3.59 0.33 
C33: trachea 1 0.01% <0.01% 0.05 <0.01 1 0.01% <0.01% 0.03 <0.01 2 0.01% <0.01% 0.04 <0.01 
C34: lung 879 10.04% 5.20% 36.97 3.01 1,231 12.55% 7.89% 60.65 4.65 2,110 11.36% 6.49% 47.56 3.83 
C37: thymus 2 0.03% 0.01% 0.10 0.01 4 0.04% 0.03% 0.20 0.02 6 0.03% 0.02% 0.15 0.01 
C38: mediastinum 5 0.05% 0.03% 0.17 0.01 6 0.06% 0.04% 0.26 0.02 11 0.06% 0.03% 0.22 0.02 
C39: other chest 0 0.00% 0.00% 
  
1 0.01% <0.01% 0.02    <0.01          1 0.01% <0.01% 0.01     <0.01          
C40: bones, joints of limbs 6 0.06% 0.03% 0.24 0.01 10 0.11% 0.07% 0.46 0.04 16 0.09% 0.05% 0.35 0.03 
C41: bones, joints head and trunk 7 0.08% 0.04% 0.27 0.02 9 0.10% 0.06% 0.42 0.03 16 0.09% 0.05% 0.35 0.02 
C43: melanoma skin 463 5.28% 2.74% 19.67 1.58 349 3.56% 2.24% 16.69 1.27 812 4.37% 2.50% 18.02 1.43 
C44: non-melanoma skin (NMSC) 3,575 - 21.16% 147.18 11.03 4,410 - 28.27% 216.31 15.24 7,985 - 24.57% 177.86 13.14 
C45: mesothelioma 5 0.06% 0.03% 0.21 0.02 30 0.31% 0.19% 1.47 0.12 35 0.19% 0.11% 0.79 0.07 
C46: Kaposi's sarcoma 1 0.02% 0.01% 0.05 <0.01 4 0.04% 0.03% 0.19 0.02 5 0.03% 0.02% 0.12 0.01 
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ICD10 cancer site  
(INCIDENCE 2008-2010) 
FEMALES MALES TOTAL 
‡all invasive cancers minus NMSC (C44) 
C00-C43, C45-C96 
†ASR/100,000 
*cumulative risk (%) to age 75 years  
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
C47: peripheral nerves 4 0.04% 0.02% 0.18 0.01 4 0.04% 0.03% 0.19 0.01 8 0.04% 0.02% 0.18 0.01 
C48: peritoneum 13 0.15% 0.08% 0.59 0.04 5 0.05% 0.03% 0.22 0.01 18 0.10% 0.06% 0.41 0.03 
C49: connective tissues 40 0.46% 0.24% 1.76 0.15 63 0.64% 0.40% 3.00 0.21 103 0.55% 0.32% 2.31 0.18 
C50: breast 2,767 31.58% 16.37% 125.43 10.06 22 0.22% 0.14% 1.06 0.08 2,789 15.02% 8.58% 64.65 5.20 
C51: vulva 48 0.55% 0.28% 1.97 0.15 - 
    
48 0.26% 0.15% 1.05 0.08 
C52: vagina 9 0.10% 0.05% 0.41 0.04 - 
    
9 0.05% 0.03% 0.21 0.02 
C53: cervix 308 3.51% 1.82% 13.34 1.04 - 
    
308 1.66% 0.95% 6.7 0.52 
C54: corpus uteri 389 4.44% 2.30% 17.87 1.64 - 
    
389 2.09% 1.20% 9.16 0.83 
C55: uterus nos 27 0.30% 0.16% 1.14 0.09 - 
    
27 0.14% 0.08% 0.6 0.04 
C56: ovary 345 3.94% 2.04% 15.10 1.27 - 
    
345 1.86% 1.06% 7.86 0.64 
C57: other female genital 13 0.15% 0.08% 0.55 0.05 - 
    
13 0.07% 0.04% 0.29 0.02 
C58: placenta 2 0.02% 0.01% 0.08 0.01 - 
    
2 0.01% <0.01% 0.04 <0.01 
C60: penis - 
    
26 0.27% 0.17% 1.27 0.09 26 0.14% 0.08% 0.60 0.05 
C61: prostate - 
    
3,014 30.73% 19.32% 150.63 12.85 3,014 16.23% 9.27% 71.64 6.63 
C62: testis - 
    
175 1.78% 1.12% 6.96 0.50 175 0.94% 0.54% 3.51 0.25 
C63: other male genital - 
    
2 0.02% 0.01% 0.12 0.01 2 0.01% <0.01% 0.05 <0.01 
C64: kidney 174 1.99% 1.03% 7.56 0.64 312 3.18% 2.00% 15.21 1.25 486 2.62% 1.50% 11.19 0.95 
C65: renal pelvis 6 0.07% 0.04% 0.25 0.02 11 0.11% 0.07% 0.53 0.04 17 0.09% 0.05% 0.38 0.03 
C66: ureter 8 0.09% 0.05% 0.30 0.02 9 0.10% 0.06% 0.46 0.04 17 0.09% 0.05% 0.38 0.03 
C67: bladder 124 1.42% 0.73% 4.85 0.35 310 3.16% 1.99% 15.36 1.01 434 2.34% 1.34% 9.46 0.68 
C68: other urinary 3 0.03% 0.02% 0.11 0.01 2 0.02% 0.01% 0.10 0.01 5 0.03% 0.02% 0.11 0.01 
C69: eye 17 0.19% 0.10% 0.72 0.05 20 0.20% 0.13% 0.98 0.08 37 0.20% 0.11% 0.85 0.07 
C70: meninges 7 0.08% 0.04% 0.29 0.02 6 0.06% 0.04% 0.27 0.02 13 0.07% 0.04% 0.29 0.02 
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ICD10 cancer site  
(INCIDENCE 2008-2010) 
FEMALES MALES TOTAL 
‡all invasive cancers minus NMSC (C44) 
C00-C43, C45-C96 
†ASR/100,000 
*cumulative risk (%) to age 75 years  
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
C71: brain 135 1.54% 0.80% 5.98 0.49 183 1.87% 1.17% 8.76 0.76 318 1.71% 0.98% 7.34 0.62 
C72: spinal cord 8 0.10% 0.05% 0.40 0.03 4 0.04% 0.03% 0.19 0.02 12 0.07% 0.04% 0.30 0.02 
C73: thyroid 129 1.47% 0.76% 5.62 0.45 48 0.49% 0.31% 2.22 0.17 177 0.95% 0.54% 3.91 0.31 
C74: adrenal 9 0.10% 0.05% 0.4 0.03 7 0.07% 0.04% 0.32 0.02 16 0.08% 0.05% 0.36 0.02 
C75: other endocrine 4 0.05% 0.03% 0.19 0.01 7 0.07% 0.04% 0.31 0.02 11 0.06% 0.03% 0.24 0.02 
C76: ill-defined site 11 0.13% 0.07% 0.41 0.03 6 0.06% 0.04% 0.33 0.02 17 0.09% 0.05% 0.37 0.03 
C80: unknown primary site 254 2.90% 1.50% 9.55 0.64 228 2.32% 1.46% 11.21 0.75 482 2.60% 1.48% 10.31 0.70 
C81: Hodgkin's lymphoma 57 0.65% 0.34% 2.46 0.19 71 0.72% 0.46% 3.20 0.26 128 0.69% 0.39% 2.83 0.22 
C82: follicular non-Hodgkin’s lymphoma 78 0.89% 0.46% 3.54 0.32 70 0.71% 0.45% 3.38 0.29 148 0.80% 0.46% 3.45 0.31 
C83: diffuse non-Hodgkin’s lymphoma 123 1.41% 0.73% 5.13 0.41 158 1.61% 1.01% 7.62 0.59 281 1.52% 0.87% 6.32 0.50 
C84: peripheral and cutaneous T cell 
lymphoma 
20 0.23% 0.12% 0.87 0.06 35 0.36% 0.23% 1.70 0.14 55 0.30% 0.17% 1.26 0.10 
C85: other and unspecified NHL 84 0.96% 0.50% 3.60 0.30 85 0.87% 0.54% 4.08 0.30 169 0.91% 0.52% 3.79 0.30 
C82-C85: all non-Hodgkin’s lymphoma 306 3.49% 1.81% 13.14 1.09 349 3.55% 2.24% 16.79 1.31 655 3.52% 2.01% 14.82 1.20 
C81-C85: lymphoma (total) 363 4.14% 2.15% 15.60 1.28 420 4.28% 2.69% 19.99 1.57 783 4.21% 2.41% 17.65 1.42 
C88: malignant immunoproliferative 
disease 
6 0.07% 0.04% 0.26 0.02 10 0.10% 0.06% 0.49 0.04 16 0.09% 0.05% 0.37 0.03 
C90: multiple myeloma 101 1.16% 0.60% 4.16 0.34 137 1.39% 0.88% 6.77 0.54 238 1.28% 0.73% 5.35 0.44 
C91: lymphoid leukaemia 98 1.12% 0.58% 4.32 0.34 158 1.61% 1.01% 7.72 0.61 256 1.38% 0.79% 5.91 0.48 
C92: myeloid leukaemia 71 0.81% 0.42% 3.04 0.24 97 0.99% 0.62% 4.67 0.34 168 0.91% 0.52% 3.77 0.29 
C93: monocytic leukaemia 2 0.02% 0.01% 0.09 0.01 2 0.02% 0.01% 0.09 0.01 4 0.02% 0.01% 0.08 0.01 
C94: other specified leukaemia 4 0.05% 0.02% 0.19 0.02 6 0.06% 0.04% 0.27 0.02 10 0.05% 0.03% 0.23 0.02 
C95: unspecified leukaemia 16 0.18% 0.09% 0.59 0.03 16 0.16% 0.10% 0.80 0.04 32 0.17% 0.10% 0.67 0.04 
C91-C95: leukaemia (total) 191 2.18% 1.13% 8.22 0.64 279 2.84% 1.79% 13.55 1.02 470 2.53% 1.45% 10.65 0.83 
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ICD10 cancer site  
(INCIDENCE 2008-2010) 
FEMALES MALES TOTAL 
‡all invasive cancers minus NMSC (C44) 
C00-C43, C45-C96 
†ASR/100,000 
*cumulative risk (%) to age 75 years  
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
annual 
average 
2008- 
2010 
‡% of all 
invasive  
cancers 
% of all 
registered 
cancers 
†ASR *risk to  
age 
75yrs 
C96: other lymphoid and haematopoietic 1 0.01% <0.01% 0.04 0.01 1 0.01% <0.01% 0.07 0.01 2 0.01% <0.01% 0.05 <0.01 
D03: in situ: melanoma 235 - 1.39% 10.43 0.93 186 - 1.19% 9.09 0.75 421 - 1.30% 9.66 0.84 
D04: in situ: carcinoma of skin 845 - 5.00% 34.05 2.78 506 - 3.24% 24.94 1.93 1,351 - 4.16% 29.9 2.36 
D05: in situ: breast 333 - 1.97% 15.82 1.35 1 - 0.01% 0.06 0.01 334 - 1.03% 7.98 0.68 
D06: in situ: cervix 2,507 - 14.84% 96.7 6.72 - - 
   
2,507 - 7.72% 47.81 3.38 
D32-D33: benign: brain & CNS 101 - 0.60% 4.39 0.35 43 - 0.28% 2.04 0.15 144 - 0.44% 3.25 0.25 
D42-D43: uncertain: brain & CNS 24 - 0.14% 1.12 0.09 27 - 0.17% 1.25 0.10 51 - 0.16% 1.19 0.09 
D00-D48 (excluding D codes specified) 518 - 3.06% 22.07 1.78 618 - 3.96% 30.14 2.33 1,135 - 3.49% 25.47 2.05 
D00-D48: All non-invasive cancers 4,563 - 27.00% 184.58 13.31 1,381 - 8.85% 67.53 5.17 5,944 - 18.29% 125.25 9.30 
C00-C43, C45-C96: All invasive minus NMSC 8,761 100% 51.84% 377.42 26.61 9,809 100% 62.88% 481.58 32.72 18,570 100% 57.14% 422.75 29.70 
C00-C96: All invasive cancers 12,336 - 73.00% 524.6 34.7 14,219 - 91.15% 697.89 42.97 26,555 - 81.71% 600.61 38.94 
C00-D48: All registered cancers 16,899 - 100% 709.17 43.39 15,600 - 100% 765.42 45.92 32,499 - 100% 725.86 44.62 
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APPENDIX II: SUMMARY TABLE - CANCER DEATHS 2010 
 
ICD10 CANCER SITE 
 
FEMALES MALES TOTAL 
‡All invasive cancer deaths C00-C96 
†ASMR: Age standardised rate (mortality)/100,000 
(standardised to the European population) 
*cumulative risk (%)  of death to age 75 years  
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
C00: lip 0 0.00% 0.00% 
  
4 0.09% 0.09% 0.19 0.01 4 0.05% 0.05% 0.08 <0.01 
C01: base of tongue 0 0.00% 0.00% 
  
2 0.05% 0.05% 0.10 0.01 2 0.02% 0.02% 0.05 <0.01 
C02: other tongue 12 0.31% 0.30% 0.47 0.03 18 0.42% 0.41% 0.89 0.07 30 0.37% 0.36% 0.67 0.05 
C03: gum 1 0.03% 0.03% 0.05 0.01 1 0.02% 0.02% 0.04 <0.01 2 0.02% 0.02% 0.05 0.01 
C04: floor of mouth 3 0.08% 0.08% 0.13 0.02 2 0.05% 0.05% 0.09 0.01 5 0.06% 0.06% 0.12 0.01 
C05: palate 2 0.05% 0.05% 0.06 <0.01 1 0.02% 0.02% 0.05 0.01 3 0.04% 0.04% 0.06 <0.01 
C06: other mouth 11 0.28% 0.28% 0.42 0.04 3 0.07% 0.07% 0.16 0.01 14 0.17% 0.17% 0.30 0.02 
C07: parotid 0 0.00% 0.00% 
  
8 0.19% 0.18% 0.38 0.02 8 0.10% 0.10% 0.16 0.01 
C08: other salivary 3 0.08% 0.08% 0.12 0.01 1 0.02% 0.02% 0.05 0.01 4 0.05% 0.05% 0.09 0.01 
C09: tonsil 3 0.08% 0.08% 0.15 0.01 12 0.28% 0.27% 0.57 0.05 15 0.18% 0.18% 0.34 0.03 
C10: oropharynx 1 0.03% 0.03% 0.05 0.01 8 0.19% 0.18% 0.39 0.01 9 0.11% 0.11% 0.19 0.01 
C11: nasopharynx 1 0.03% 0.03% 0.02 <0.01 8 0.19% 0.18% 0.37 0.04 9 0.11% 0.11% 0.19 0.02 
C12: pyriform 0 0.00% 0.00% 
  
3 0.07% 0.07% 0.14 0.01 3 0.04% 0.04% 0.07 <0.01 
C13: hypopharynx 2 0.05% 0.05% 0.07 <0.01 5 0.12% 0.11% 0.22 0.02 7 0.09% 0.08% 0.14 0.01 
C14: other mouth/pharynx 6 0.16% 0.15% 0.21 0.01 7 0.16% 0.16% 0.35 0.03 13 0.16% 0.15% 0.27 0.02 
C01-C14: mouth & pharynx 45 1.16% 1.13% 1.75 0.14 79 1.85% 1.79% 3.79 0.27 124 1.52% 1.48% 2.69 0.20 
C15: oesophagus 113 2.92% 2.83% 4.06 0.25 220 5.15% 4.99% 10.53 0.84 333 4.09% 3.97% 7.13 0.55 
C16: stomach 136 3.52% 3.41% 5.02 0.32 180 4.22% 4.09% 8.54 0.63 316 3.88% 3.76% 6.68 0.48 
C17: small intestine 8 0.21% 0.20% 0.27 0.01 10 0.23% 0.23% 0.46 0.03 18 0.22% 0.21% 0.37 0.02 
C18: colon 229 5.92% 5.74% 8.32 0.52 275 6.44% 6.24% 13.24 0.89 504 6.20% 6.00% 10.54 0.70 
C19: rectosigmoid 112 2.90% 2.81% 4.32 0.31 158 3.70% 3.59% 7.52 0.54 270 3.32% 3.22% 5.73 0.43 
C20: rectum 62 1.60% 1.55% 2.31 0.16 96 2.25% 2.18% 4.67 0.25 158 1.94% 1.88% 3.29 0.20 
C21: anus 4 0.10% 0.10% 0.14 0.01 6 0.14% 0.14% 0.32 0.01 10 0.12% 0.12% 0.20 0.01 
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ICD10 CANCER SITE 
 
FEMALES MALES TOTAL 
‡All invasive cancer deaths C00-C96 
†ASMR: Age standardised rate (mortality)/100,000 
(standardised to the European population) 
*cumulative risk (%)  of death to age 75 years  
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
C18-C21: colorectal 407 10.53% 10.20% 15.10 0.99 535 12.53% 12.15% 25.75 1.68 942 11.58% 11.22% 19.76 1.34 
C22: liver 101 2.61% 2.53% 3.78 0.29 159 3.72% 3.61% 7.65 0.58 260 3.20% 3.10% 5.62 0.43 
C23: gallbladder 16 0.41% 0.40% 0.63 0.05 3 0.07% 0.07% 0.15 0.01 19 0.23% 0.23% 0.40 0.03 
C24: other biliary 7 0.18% 0.18% 0.27 0.02 5 0.12% 0.11% 0.24 0.01 12 0.15% 0.14% 0.25 0.02 
C25: pancreas 228 5.90% 5.72% 8.78 0.68 244 5.71% 5.54% 11.85 0.90 472 5.80% 5.62% 10.19 0.79 
C26: other digestive 62 1.60% 1.55% 2.25 0.17 75 1.76% 1.70% 3.73 0.21 137 1.68% 1.63% 2.83 0.19 
C30: nasal cavity/middle ear 0 0.00% 0.00% 
  
1 0.02% 0.02% 0.04 <0.01 1 0.01% 0.01% 0.01 <0.01 
C31: sinuses 1 0.03% 0.03% 0.02 <0.01 3 0.07% 0.07% 0.13 0.00 4 0.05% 0.05% 0.07 <0.01 
C32: larynx 8 0.21% 0.20% 0.30 0.03 48 1.12% 1.09% 2.37 0.18 56 0.69% 0.67% 1.27 0.10 
C33: trachea 1 0.03% 0.03% 0.03 <0.01 1 0.02% 0.02% 0.05 0.01 2 0.02% 0.02% 0.04 <0.01 
C34: lung 716 18.53% 17.95% 28.97 2.36 977 22.88% 22.18% 47.34 3.50 1693 20.81% 20.17% 37.00 2.93 
C37: thymus 1 0.03% 0.03% 0.04 <0.01 1 0.02% 0.02% 0.05 <0.01 2 0.02% 0.02% 0.04 <0.01 
C38: mediastinum 6 0.16% 0.15% 0.25 0.02 3 0.07% 0.07% 0.15 0.02 9 0.11% 0.11% 0.21 0.02 
C39: other chest 0 0.00% 0.00% 
  
1 0.02% 0.02% 0.04 <0.01 1 0.01% 0.01% 0.01 <0.01 
C40: bones, joints of limbs 2 0.05% 0.05% 0.07 <0.01 0 0.00% 0.00% 
  
2 0.02% 0.02% 0.04 <0.01 
C41: bones, joints head and trunk 8 0.21% 0.20% 0.30 0.01 9 0.21% 0.20% 0.43 0.02 17 0.21% 0.20% 0.35 0.02 
C43: melanoma skin 60 1.55% 1.50% 2.27 0.16 85 1.99% 1.93% 4.04 0.27 145 1.78% 1.73% 3.06 0.21 
C44: non-melanoma skin 26 0.67% 0.65% 0.86 0.05 57 1.33% 1.29% 2.83 0.09 83 1.02% 0.99% 1.61 0.07 
C45: mesothelioma 4 0.10% 0.10% 0.18 <0.01 35 0.82% 0.79% 1.67 0.12 39 0.48% 0.46% 0.86 0.07 
C46: Kaposi's sarcoma 0 0.00% 0.00% 
  
1 0.02% 0.02% 0.04 <0.01 1 0.01% 0.01% 0.02 <0.01 
C47: peripheral nerves 1 0.03% 0.03% 0.04 <0.01 0 0.00% 0.00% 
  
1 0.01% 0.01% 0.02 <0.01 
C48: peritoneum 11 0.28% 0.28% 0.37 0.01 6 0.14% 0.14% 0.31 0.03 17 0.21% 0.20% 0.35 0.02 
C49: connective tissues 22 0.57% 0.55% 0.91 0.07 19 0.44% 0.43% 0.87 0.07 41 0.50% 0.49% 0.89 0.07 
C50: breast 649 16.79% 16.27% 26.65 2.17 10 0.23% 0.23% 0.49 0.03 659 8.10% 7.85% 14.35 1.10 
C51: vulva 19 0.49% 0.48% 0.66 0.05 - 
    
19 0.23% 0.23% 0.37 0.02 
C52: vagina 5 0.13% 0.13% 0.20 0.02 - 
    
5 0.06% 0.06% 0.11 0.01 
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ICD10 CANCER SITE 
 
FEMALES MALES TOTAL 
‡All invasive cancer deaths C00-C96 
†ASMR: Age standardised rate (mortality)/100,000 
(standardised to the European population) 
*cumulative risk (%)  of death to age 75 years  
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
C53: cervix 88 2.28% 2.21% 3.82 0.32 - 
    
88 1.08% 1.05% 1.96 0.16 
C54: corpus uteri 73 1.89% 1.83% 2.94 0.28 - 
    
73 0.90% 0.87% 1.58 0.14 
C55: uterus nos 26 0.67% 0.65% 1.00 0.07 - 
    
26 0.32% 0.31% 0.55 0.04 
C56: ovary 286 7.40% 7.17% 11.96 1.04 - 
    
286 3.52% 3.41% 6.33 0.52 
C57: other female genital 5 0.13% 0.13% 0.21 0.02 - 
    
5 0.06% 0.06% 0.11 0.01 
C58: placenta 0 0.00% 0.00% 
  
- 
    
0 0.00% 0.00% 
  C60: penis - 
    
5 0.12% 0.11% 0.27 0.02 5 0.06% 0.06% 0.11 0.01 
C61: prostate - 
    
533 12.48% 12.10% 26.18 1.02 533 6.55% 6.35% 10.33 0.51 
C62: testis - 
    
5 0.12% 0.11% 0.23 0.02 5 0.06% 0.06% 0.11 0.01 
C63: other male genital 0 0.00% 0.00% 
  
1 0.02% 0.02% 0.06 <0.01 1 0.01% 0.01% 0.02 <0.01 
C64: kidney 57 1.47% 1.43% 2.11 0.14 127 2.97% 2.88% 6.13 0.40 184 2.26% 2.19% 3.89 0.27 
C65: renal pelvis 0 0.00% 0.00% 
  
3 0.07% 0.07% 0.14 0.01 3 0.04% 0.04% 0.07 <0.01 
C66: ureter 2 0.05% 0.05% 0.07 0.01 3 0.07% 0.07% 0.15 0.02 5 0.06% 0.06% 0.11 0.01 
C67: bladder 65 1.68% 1.63% 2.35 0.16 120 2.81% 2.72% 5.79 0.23 185 2.27% 2.20% 3.70 0.20 
C68: other urinary 2 0.05% 0.05% 0.05 <0.01 7 0.16% 0.16% 0.35 0.03 9 0.11% 0.11% 0.19 0.01 
C69: eye 4 0.10% 0.10% 0.15 0.02 5 0.12% 0.11% 0.24 0.02 9 0.11% 0.11% 0.20 0.02 
C70: meninges 4 0.10% 0.10% 0.17 0.02 0 0.00% 0.00% 
  
4 0.05% 0.05% 0.09 0.01 
C71: brain 92 2.38% 2.31% 3.98 0.34 139 3.26% 3.16% 6.53 0.52 231 2.84% 2.75% 5.18 0.43 
C72: spinal cord 0 0.00% 0.00% 
  
0 0.00% 0.00% 
  
0 0.00% 0.00% 
  C73: thyroid 14 0.36% 0.35% 0.53 0.04 11 0.26% 0.25% 0.53 0.04 25 0.31% 0.30% 0.54 0.04 
C74: adrenal 4 0.10% 0.10% 0.18 0.01 4 0.09% 0.09% 0.18 0.01 8 0.10% 0.10% 0.18 0.01 
C75: other endocrine 2 0.05% 0.05% 0.09 0.01 3 0.07% 0.07% 0.14 0.01 5 0.06% 0.06% 0.11 0.01 
C76: ill-defined site 9 0.23% 0.23% 0.35 0.02 12 0.28% 0.27% 0.57 0.03 21 0.26% 0.25% 0.44 0.03 
C80: unknown primary site 163 4.22% 4.09% 5.89 0.38 124 2.90% 2.81% 5.93 0.37 287 3.53% 3.42% 5.92 0.37 
C81: Hodgkin's lymphoma 8 0.21% 0.20% 0.25 0.01 10 0.23% 0.23% 0.47 0.04 18 0.22% 0.21% 0.37 0.02 
C82: follicular non-Hodgkin’s lymphoma 3 0.08% 0.08% 0.11 0.01 5 0.12% 0.11% 0.25 0.01 8 0.10% 0.10% 0.17 0.01 
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ICD10 CANCER SITE 
 
FEMALES MALES TOTAL 
‡All invasive cancer deaths C00-C96 
†ASMR: Age standardised rate (mortality)/100,000 
(standardised to the European population) 
*cumulative risk (%)  of death to age 75 years  
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
deaths 
2010 
‡% of all 
invasive 
cancer 
deaths 
% of all 
registered 
cancer 
deaths 
†ASMR *risk of  
death 
to 75yrs 
C83: diffuse non-Hodgkin’s lymphoma 10 0.26% 0.25% 0.38 0.02 14 0.33% 0.32% 0.68 0.03 24 0.30% 0.29% 0.51 0.02 
C84: peripheral and cutaneous T cell lymphoma 9 0.23% 0.23% 0.38 0.02 12 0.28% 0.27% 0.60 0.05 21 0.26% 0.25% 0.48 0.03 
C85: other and unspecified NHL 76 1.97% 1.91% 2.93 0.23 103 2.41% 2.34% 4.96 0.32 179 2.20% 2.13% 3.82 0.28 
C82-C85: all non-Hodgkin’s lymphoma 98 2.54% 2.46% 3.80 0.27 134 3.14% 3.04% 6.48 0.42 232 2.85% 2.76% 4.99 0.34 
C81-C85: lymphoma (total) 106 2.74% 2.66% 4.06 0.28 144 3.37% 3.27% 6.95 0.45 250 3.07% 2.98% 5.36 0.37 
C88: malignant immunoproliferative disease 0 0.00% 0.00% 
  
3 0.07% 0.07% 0.12 0.01 3 0.04% 0.04% 0.06 <0.01 
C90: multiple myeloma 85 2.20% 2.13% 3.06 0.22 67 1.57% 1.52% 3.28 0.21 152 1.87% 1.81% 3.13 0.22 
C91: lymphoid leukaemia 29 0.75% 0.73% 1.02 0.05 44 1.03% 1.00% 2.16 0.15 73 0.90% 0.87% 1.54 0.10 
C92: myeloid leukaemia 47 1.22% 1.18% 1.79 0.13 70 1.64% 1.59% 3.39 0.25 117 1.44% 1.39% 2.51 0.19 
C93: monocytic leukaemia 1 0.03% 0.03% 0.04 <0.01 0 0.00% 0.00% 
  
1 0.01% 0.01% 0.02 <0.01 
C94: other specified leukaemia 0 0.00% 0.00% 
  
1 0.02% 0.02% 0.04 <0.01 1 0.01% 0.01% 0.01 <0.01 
C95: unspecified leukaemia 10 0.26% 0.25% 0.31 0.01 13 0.30% 0.30% 0.63 0.04 23 0.28% 0.27% 0.47 0.03 
C91-C95: leukaemia (total) 87 2.25% 2.18% 3.15 0.19 128 3.00% 2.91% 6.22 0.44 215 2.64% 2.56% 4.56 0.32 
C96: other lymphoid and haematopoietic 1 0.03% 0.03% 0.04 <0.01 1 0.02% 0.02% 0.05 0.01 2 0.02% 0.02% 0.05 <0.01 
D00-D48: All non-invasive cancer deaths 124 - 3.11% 4.11 0.22 135 - 3.06% 6.38 0.25 259 - 3.09% 5.00 0.23 
C00-C96: All invasive cancer deaths 3865 100% 96.89% 151.14 10.94 4270 100% 96.94% 206.37 12.77 8135 100% 96.91% 173.24 11.86 
C00-D48: Total cancer deaths (invasive & non-invasive) 3989 - 100% 155.26 11.14 4405 - 100% 212.75 12.99 8394 - 100% 178.24 12.07 
Mortality data provided by the Central Statistics Office (www.cso.ie) 
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APPENDIX III: INCIDENCE AND MORTALITY: IRELAND AND OTHER EUROPEAN COUNTRIES, 2012 
1. European Cancer Observatory (ECO). http://eco.iarc.fr/. 
 
Estimated cancer incidence and mortality in Europe 2012:  mouth and pharynx (C01-14) 
  
 
Estimated cancer incidence and mortality in Europe 2012: oesophagus (C15) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: stomach (C16) 
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Estimated cancer incidence and mortality in Europe 2012: pancreas (C25) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: melanoma skin cancer (C43) 
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Estimated cancer incidence and mortality in Europe 2012: cervix  (C53) 
  
0 10 20 30 40 
Switzerland 
Finland 
Greece 
Austria 
Luxembourg 
Italy 
UK 
France 
Netherlands 
Sweden 
Spain 
Germany 
Belgium 
Portugal 
EU overall 
Norway 
Slovenia 
Denmark 
Ireland 
Poland 
Czech Republic 
Slovakia 
Hungary 
Latvia 
Estonia 
Bulgaria 
Lithuania 
Romania 
cases per 100,000 per year (European age standardised) 
incidence 
0 5 10 15 
Finland 
Switzerland 
Italy 
Netherlands 
UK 
Germany 
Greece 
Denmark 
France 
Sweden 
Belgium 
Spain 
Austria 
Norway 
EU overall 
Luxembourg 
Slovenia 
Czech Republic 
Ireland 
Portugal 
Estonia 
Hungary 
Slovakia 
Poland 
Latvia 
Bulgaria 
Lithuania 
Romania 
cases per 100,000 per year (European age standardised) 
mortality 
 Cancer in Ireland 2013: Annual report Page  52 
 
APPENDIX III-continued  
 
Estimated cancer incidence and mortality in Europe 2012:  corpus uteri  (C54) 
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Estimated cancer incidence and mortality in Europe 2012:  ovary  (C56) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: testis  (C62) 
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Estimated cancer incidence and mortality in Europe 2012: kidney, renal pelvis and  ureter  (C64-66) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: bladder (C67) 
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Estimated cancer incidence and mortality in Europe 2012: meninges, brain, spinal cord (C70-72) 
  
20 10 0 10 20 
Hungary 
Austria 
Netherlands 
Estonia 
Italy 
Switzerland 
France 
UK 
Finland 
Spain 
Germany 
Czech Republic 
Belgium 
Luxembourg 
Slovenia 
EU overall 
Portugal 
Romania 
Ireland 
Denmark 
Lithuania 
Slovakia 
Greece 
Bulgaria 
Norway 
Poland 
Latvia 
Sweden 
cases per 100,000 per year (European age standardised) 
incidence 
females 
males 
10 5 0 5 10 
Hungary 
France 
Austria 
Belgium 
Spain 
Finland 
Germany 
Italy 
Czech Republic 
Switzerland 
UK 
EU overall 
Portugal 
Netherlands 
Luxembourg 
Sweden 
Norway 
Slovenia 
Denmark 
Ireland 
Slovakia 
Estonia 
Lithuania 
Romania 
Poland 
Latvia 
Bulgaria 
Greece 
cases per 100,000 per year (European age standardised) 
mortality 
females 
males 
 Cancer in Ireland 2013: Annual report Page  55 
 
APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012:  thyroid (C73) 
  
 
 
 
Estimated cancer incidence and mortality in Europe 2012: Hodgkin’s lymphoma (C81) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: non-Hodgkin’s lymphoma & other lymphoid/haematopoietic  
(C82-85,C96) 
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Estimated cancer incidence and mortality in Europe 2012: malignant immunoproliferative and multiple myeloma  
(C88 and C90) 
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APPENDIX III-continued  
Estimated cancer incidence and mortality in Europe 2012: leukaemia (C91-95) 
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APPENDIX IV: TRENDS IN INCIDENCE AND MORTALITY: 1994-2010 
mouth and pharynx: C01-14 oesophagus: C15 stomach: C16 
   
pancreas: C25 non-melanoma skin cancer: C44 kidney: C64 
   
See Table 9 for annual percentage change (APC) estimates 
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APPENDIX IV-continued  
bladder: C67 brain & CNS: C70-C72 thyroid: C73 
   
lymphoma (total): C81-C85 Hodgkin's disease: C81 non-Hodgkin’s lymphoma: C82-C85 
   
See Table 9 for annual percentage change (APC) estimates 
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APPENDIX IV-continued  
multiple myeloma: C90 leukaemia (total): C91-C95 ovary: C56 
   
corpus uteri: C54 testis: C62  
  
 
See Table 9 for annual percentage change (APC) estimates 
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